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The purpose of this study was to examine the influences of estrogen and
chemokine receptor-5 (CCR5) on immune response and Chlamydia pathogenesis.
Chlamydia trachomatis is the most common bacteria that causes sexually transmitted
disease (STD) worldwide. Clearance of chlamydia infections is due to a robust T cell
(Thl) response. Immunological and hormonal factors such as 17P-estradiol and
chemokine and/or chemokine receptors may influence the induction of protective
immunity against chlamydia infections. In fact, estrogens such as I7P-estradiol could
influence the genital mucosal immunobiology, including cytokine expression and
recruitment and trafficking of leukocytes into the reproductive tract.
Genetically engineered knockout animals, molecular and immunological
techniques were used to test the hypothesis that estrogen and CCR5 play pivotal roles in
the pathogenesis and immunity against chlamydia infection by modulating the chemokine
production and Thl response.
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Results indicated that in 17p-estradiol treated cells, there was an enhancement of
chlamydia inclusion bodies. Moreover, there was a decrease in the production of Thl
chemokines [regulated activated normal secreted and expressed T cells (RANTES)
Macrophage Inducible Protein-la/p (MIP-la /MIP-ip), interferon-inducible protein 10
(IP-10)]. Delayed clearance of genital infection was observed in wild-type mice that
were pretreated with estrogen. There was no comparable effect on the fertility (measured
by pregnancy rate) of estrogen treated mice during chlamydia infection and that of
untreated infected mice.
When genitally-infected wild-type (WT) and CCR5 knockout mice were
evaluated for microbiologic shedding of chlamydiae, there was a greater intensity of
infection and delayed resolution in the knockout mice. However, compared to the WT
mice, the fertility of infected CCR5KO mice was only mildly affected in the short term
and unaffected in the long term. In addition, immimobiologic analysis revealed that the
diminished capacity of CCR5KO to control acute chlamydial infection correlated with
the relatively low chemokine and cytokine expression corresponding to a poor early Th 1
response. However, reduced incidence of complications in the CCR5KO mice appears to
correlate with the low activity of long term inflammatory mediators.
The findings of this study may be helpful in the development of therapeutic
and/or preventive treatments to control the onset of genital chlamydia associated
complications.
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The family Chlamydiaceae consists of one genus Chlamydia with three species that
cause human disease C. trachomatis, C. psittaci, and C. pneumoniae. C. precorum has
not been associated with any human disease. Chlamydiae are small obligate intracellular
parasites which were previously considered to be viruses. However, they contain
deoxyribose nucleic acid (DNA), ribonucleic acid (RNA) and ribosomes for making their
own proteins and nucleic acids and now considered to be true bacteria. They possess an
inner and outer membrane similar to Gram-negative bacteria and a lipopolysaccharide,
but do not have a peptidoglycan layer. Although they synthesize most of their metabolic
intermediates, they are unable to make their own adenosine triphosphate and thus are
energy parasites. Chlamydial infectious agents have a tropism for mucosal epithelial
cells of the eyes, lungs, and reproductive tract, where they many times exist in an
asymptomatic state with the host cell acting as a natural reservoir for the bacterium
(Mather 1980; van Westereenen et al. 1998; Igietseme et al. 1996). Transmission can
occur through direct contact and aerosol, and requires no alternate vector, although
infections can be transmitted from flies to ocular regions in trachoma endemic areas
(Sheff2000).
Chlamydia trachomatis is the cause of the most widely spread bacterial sexually
transmitted disease (STD) worldwide. The World Health Organization (WHO) recently
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revealed that C. trachomatis infections account for more than 90 out of 500 million
annual new STDs worldwide. In 2004,929,462 cases were reported to the Centers for
Disease Control (CDC) from 50 states and the District ofColumbia (CDC 2004). The
pathological consequences of genital infection by C. trachomatis in women are severe
sequelae associated with ascending infection including pelvic inflammatory disease
(PID), fallopian tube scarring, ectopic pregnancy and infertility. The frequent
asymptomatic nature of Chlamydia infections often result in the presentation of these
complications as the first evidence of infection. In men, the initial stage of genital
chlamydial infection involves inflammation of the urethra such as non-gonococcal
urethritis. Untreated cases result in men experiencing fever, swelling and pain in the
scrotum; symptoms of acute epididymitis, which is inflammation of the sperm ducts
ventral to the testicles. Presently, there is no evidence that this pathogen causes infertility
in men (Krause and Bohring 2003).
Chlamydial infections are treatable with antibacterials, such as tetracycline
derivatives, especially doxycycline, and the macrolides or azalides such as erythromycin
and azithromycin; however, as previously mentioned, infections are often asymptomatic,
with severe complications usually presenting as the first symptoms of an infection
(Igietseme 2002). The dilemma posed by chlamydial infections in both the developed
and developing nations has intensified efforts to design preventive and control measures,
of which frequent screening for early detection and treatment, and the administration of
an efficacious vaccine have become a priority (Igietseme 2002). However, there are
obvious difficulties in establishing acceptable and cost-effective, community-wide
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screening programs or rational antibacterial prophylaxis. Therefore, timely diagnosis
using contemporary methodologies, and application of chemotherapy to arrest silent or
persistent infections have not been established to control chlamydial infections. This
situation has resulted in the deep concern that chlamydial infections may pose a serious
threat to human reproduction, longevity and general health quality, as well as constituting
a considerable burden on national healthcare budgets and management. A vaccine is the
approach to delivering long-lasting protection to the largest number of people worldwide.
In fact, computer modeling has indicated that even a partially successful vaccination
program would have a remarkable global impact in reducing chlamydial infections,
disease prevalence and related expenditure (Moore et al. 2002). Therefore, while the
ultimate goal of a chlamydial vaccine is ideally to achieve sterilizing immimity, a vaccine
effective against disease sequelae, such as PID, blinding trachoma and tubal scarring
would be acceptable as a first-generation product. A better understanding of the
immunobiology of chlamydial infections will be crucial for vaccine design. Although
many advances have been made in chlamydia research, limited progress has been made in
defining the immune effectors that mediate chlamydia immunity.
Animal model studies have revealed that mice infected intravaginally with mouse
pneumonitis biovar of C. trachomatis (MoPn) develop a self-limiting infection, which
generally resolved in 18 to 21 days (Barron et al. 1981). Genital inoculation of mice
with MoPn initiates infection in the vaginal epithelium and ascends the epithelial surface
of the uterine horns and oviducts (Morrison et al. 1995). Infection is usually confined to
the geniteil tract mucosal epithelium. The host response occurs in two phases which
involves the secretion of chemoattractant proteins referred to as chemokines from the
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infected cell such as dendritic cells, macrophages and epithelial cells. These chemokines
include regulated on activation, normal T cell expressed and secreted (RANTES),
monocyte chemoattractant proteins (MCP-1), and macrophage inflammatory protein-1
alpha and beta (MIP-la, ip) (Belay et al. 2002). They elicit a specific immune response
by stimulating the activation and migration ofT and B cells.
The profile of immune responses measured following chlamydial infection of humans
and experimental animal models include a strong T cell response characterized by
chlamydial specific CD4^ and CD8^ T cells and their cytokines, which are induced
following exposure to Chlamydia (Igietseme 1996). Cell mediated immune (CMI)
response involving Thl cells has been foimd to be crucial for clearance of a genital
chlamydial infection (Stagg 1998; Bose et al. 1986; Moore et al. 2002; Paavonen 1989).
The importance of CMI in protection against chlamydial genital tract infection was first
demonstrated with T-cell deficient athymic (nude) mice and mice depleted of CD4^ T
cells (Morrison et al. 2002). Chlamydiae-specific CD4^ or CD8^ T cell lines and clones
also impart partial protection to naive recipient mice, however, the magnitude of
protection conferred by CD4'^ T cells is distinctly superior to that by CD8^ T cells.
Collectively, many lines of evidence strongly implicate CD4'^ T cells as an important
lymphocyte subset in mediating antichlamydial immunity. The Thl cytokine interferon
gamma (IFN-y) is essential for optimal clearance of infection from genital tract tissue
(Morrison et al. 2002). The mechanisms by which IFN- y could inhibit chlamydial
intracellular growth are numerous, due to its pleiomorphic effects on host cell function.
The two IFN- y inducible host cell functions that have received the majority of attention
in studies of chlamydial immunity are the induction of inducible nitric oxide synthase and
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of tryptophan-decyclizing enzyme indoleamine 2,3-dioxygenase (Igietseme 2002). The
production of bactericidal nitric oxide synthase resolves both primary and secondary
chlamydial infections. Conversely, the depletions of intracellular tryptophan pools by
indoleamine 2, 3-dioxygenase is inhibitory to chlamydial growth due to the parasites’
tryptophan auxotrophy (Morrison et al. 2002). The sensitivity of human strains of
chlamydia to IFN-y indicates that stimulation ofmucosal IFN-y Thl responses play a key
role in the eradication of infection (Morrison et al. 2002). Therefore, it would be
valuable to gain better insight of the factors that may regulate the induction, recruitment,
and persistence of Thl cells. In general, these factors that may regulate the T cell
processes are antigen presenting cells (APCs), cytokines/chemokines released by infected
cells, cytokine/chemokine receptors, and the hormonal environment during infection.
Belay et al. (2002) demonstrated that Chemokine Receptor-5 (CCR5) was highly
expressed on T-cells in the genital tract 21 days post chlamydial infection. The
chemokine receptor-5 (CCR5) acts as a co-receptor with the CD4^ molecule for the entry
of human immunodeficiency virus (HIV-2) into host cells (Huang et al. 1996; Dean et
al. 1996). Interestingly, chlamydia has been associated with an increased risk of human
immunodeficiency virus-related AIDS (Morrison et al. 2002; Anttila et al. 2001; and
Oshige K.S. et al. 2000). The chemokine receptor CCR5 is a member of the 7-
transmembrane, G protein-coupled receptor superfamily, fimctioning as an important
chemokine receptor that is preferentially expressed on certain leukocytes (monocytes,
cytotoxic T cells, and CD4, T-helper 1 (Thl) and dendritic cells, and binding specific
chemokines (RANTES, MIP-la, MIP-ip) that activate and induce Thl cells. As a
crucial receptor involved in T cell activation and function, a deficiency of CCR5 is
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associated with a suppression of T cell induction and leukocyte migration under certain
infectious and non-infectious conditions, suggesting that it plays a role in both infection-
related immune and inflammatory processes (Barr et al. 2005). The effect of a targeted
suppression of the critical specific T cell response on both immune-mediated microbial
clearance and the development of complications of chlamydial infection is largely
unknown.
Epidemiologic evidence suggests that infection with C. trachomatis is enhanced
by oral contraceptives (Washington et al. 1985). This link between hormonal
contraception and cervical infections is biologically plausible because estrogen and
progesterone can enhance or suppress the growth and persistence of vaginal flora
(Kaushic et al. 2000). In a quantitative review by Cottingham and Hunter (1992), it was
observed that women who chose Depo-Provera as a contraceptive experienced a three
fold increase in the risk of acquiring two of the most commonly spread bacterial STDs:
chlamydia and gonorrhea. Moreover, estrogen pretreatment has been associated with
increased chlamydia growth using in vivo and in vitro models (Rank 1989; Bose et al.
1999; Guseva 2003). The exact cause for this enhancement is yet to be studied. There is
a lack ofknowledge on the effects of hormones on the cellular and molecular effectors of
chlamydia immunity.
The purpose of this study was to investigate the influence of estrogen, and the Thl
receptor CCR5 on the pathogenesis and immunity against genital chlamydia infection.
Accordingly, both in vitro and in vivo studies were used to investigate the role of 17 p-
estradiol and chemokine receptors on T cell activation, and protection from complications
during genital chlamydia infection. The following specific aims were used to test the
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hypothesis stating that both estrogen and CCR5 play pivotal roles in the pathogenesis and
immunity against chlamydia by modulating the chemokine production and Thl response:
1) To determine the influence of estrogen on the pathogenesis and immune
response against genital chlamydia infection
la. Investigate the effects of estrogen on chlamydia infectivity and chemokine
expression during infection ofepithelial cells
lb. Evaluate the effects of estrogen on the course of infection and chemokine
production during genital chlamydia infection in mice
lc. Determine the effects of estrogen on fertility of chlamydia infected mice
2) To investigate the influence of CCR5 on the pathogenesis and immune response
against genital chlamydia infection
2a. Assess the effect of CCR5 on the course of infection and chemokine/cytokine
response in chlamydia infected mice
2b. To evaluate the effects ofCCR5 on fertility genital chlamydia infected mice
This study has revealed novel findings indicating that estrogen and CCR5 have
key roles on the immune response during chlamydia infection. This is the first study
to show the effects of estrogen and CCR5 on inflammatory cytokine response during
genital chlamydia infection. These findings may be helpful in developing therapeutic




Structure and Characteristics ofChlamydia
Chlamydia primary antigens include the 45 kilodalton (kd) glycoprotein major
outer protein (Omp 1 or MOMP), 60 kd cysteine rich protein (OMP2) and porB, a low
molecular weight protein. Ultrastructurally, chlamydiae are complex and display
attributes not found in other bacteria. The envelopes of both elementary bodies (EBs)
and reticulate bodies (RBs) have two trilaminar membranes, an outer membrane and an
inner cytoplasmic membrane (Stephens 1999); in this respect chlamydiae are similar to
other Gram-negative bacteria. Chemical evaluations have demonstrated that chlamydiae
lack muramic acid and thus do not contain peptidoglycan. Another unique ultrastructural
feature of this pathogen is the surface projections that extend from the cytoplasmic
membrane and protrude approximately 20 nm above the outer membrane. The outer
membrane complex components defined at the molecular level are LPS, MOMP, OMP2,
and OMP3. Both LPS and MOMP on RBs are surface-accessible by antibodies. OMP2
and OMP3 are developmental stage-specific cysteine-rich proteins present only in EBs
(Stephens 1999). Chlamydia trachomatis is a strict pathogen of oculogenital epithelial
cells. It is the etiologic agent of trachoma and is the leading cause of bacterial sexually
transmitted diseases (STDs) worldwide (Brunham 1999, WHO 1996). C. trachomatis
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and C. psittaci has several serovars with each species that differ in cell wall composition
and the presence ofparticular outer membrane proteins (Rank 1999). C. trachomatis
isolates consist of 15 major serovariants that can be distinguished among clinical isolates,
based on serological distinction of variation in the major outer membrane protein
(MOMP-a translation product of ompA) (Stagg 1998). Recently, genotypic
identification and confirmation of these isolates by ompA-based nucleic acid
amplification and sequencing methods have led to an alternative designation, genovar or
genotype. The classification is useful in pathologic, epidemiologic and detailed
taxonomic analysis of chlamydiae and their evolution in the microbial realm (Igietseme
2002; Morrison et al. 2002; Loomis et al. 2002; Brunham 1999). The closely related
murine strain designated MoPn was recently reclassified as C. muridarum (Everett, et al.
1999). Of the 15 odd serovars of C. trachomatis, serovars A, B, Ba, and C cause
trachoma. Serovars D to K and the Ijonphogranuloma venereum (LGV) strain LI, L2 and
L3 cause sexually transmitted genital infection in the human populations. This infection
has been associated with causing cervicitis, urethritis and complications linked to more
severe disease such as endometritis, salpingitis and pelvic inflammatory disease (PID).
LGV and D to K serovars differ biologically and pathologically. Serovars D to K are
noninvasive and may cause infection and disease that are restricted to the urogenital
mucosae (Morrison 2002). The lymphogranuloma venereum infections are invasive and
often ulcerative with lymphatic tissue involvement (e.g. inguinal bubo) (Yang 1998;
Patton 1992). These infections are endemic in certain developing nations, including parts
of Africa, Asia, South America, and the Caribbean (Rank 1999). Lymphogranuloma
venereum transiently infect epithelial cells, invade the submucosae to infect
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macrophages, the macrophages then facilitate the dissemination of infection to regional
draining lymph nodes.
In fact, genital infections by the different genovars of C. trachomatis constitutes
the most common bacterial STD in the United States and several other industrialized
nations, including the United Kingdom, Germany, Japan, and France. The World Health
Organization (WHO) recently revealed that C. trachomatis infections account for more
than 90 of 500 million annual new STDs worldwide. The United States alone spends
over $2 billion annually on four million reported cases (WHO 1996, CDC 2004); this
constitutes an enormous morbidity and socioeconomic burden of chlamydial infections.
Moreover, reports suggesting that genital chlamydial infection may be on the rise
(Igietseme 2002), and could predispose to HIV-related AIDS (Cohen 2000; Cohen 1999)
and human papilloma virus-associated cervical dysplasia, have heightened these concerns
(Gopalkrishna et al. 2000; Hakama et al. 2000).
Chlamydia pneumoniae (also known as Chlamydophila pneumoniae) was
previously known to cause mild to sub-lethal acute respiratory infections that may on
occasion progress to pharyngitis, bronchitis and even pneumonia. The pathogen has
recently been associated with atherosclerosis, adult-onset asthma and certain other
chronic diseases (Igietseme 2002; Martson 2002; Rajalingam 2001). The zoonotic C.
psittaci constitutes an occupational hazard for workers in the poultry and farming
industry, and persons exposed to infected avian species (Buzoni-Gatel 1992). In animal
and birds, C. psittaci infections cause psittacosis, hepatitis, mastitis, conjunctivitis,
pneumonia, abortions and diarrhea, but in humans the infection causes a psittacosis-like
disease that may on rare cases become systemic and fatal. Finally, the fourth species of
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Chlamydia, C. pecorum, has not been associated with any human disease (Brunham
1999).
The developmental cycle ofChlamydia is characterized by an alternation between
two structurally and physiologically distinct forms: the infectious elementary body (EB)
and the non-infectious replicative reticulate body (RB).
The EB possesses a rigid outer membrane that is extensively cross-linked by
disulfide bonds. Because of their rigid outer membrane EBs are resistant to harsh
environmental conditions encountered when the chlamydia are outside of their eukaryotic
host cells. The metabolically active and vegetative intracytoplasmic RB possesses a
fragile membrane lacking the extensive disulfide bonds characteristic of the EB.
Chlamydial infection is initiated by the attachment via receptors to a susceptible
host cell of the EB. The EBs are endocytosed by epithelial cells. EBs become
metabolically active, and replicate in modified vacuoles, termed inclusions. The EB is
rapidly transformed into a RB, which replicates by binary fission within the confines of
the inclusion. As the developmental cycle progresses, progeny Chlamydia condense into
infectious elementary bodies that are released by exocytosis or host cell lysis (Fig. 1).
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Chlamydia Infectious Oycle
Figure 1. Chlamydia Developmental Cycle (used by permission)
Host Immune Response during Genital Chlamydia Infeetion
Different animal models have been developed to study the pathogenesis and host
immune response to C. trachomatis infection as a prerequisite for accumulating
information to guide the design of prevention strategies, including an effective vaccine
against chlamydia. Of these animal models, most information, both in terms of
pathologic features and immunobiology of the genital infection, has emerged from
experimental infections and immunization studies in mice, guinea pigs and monkey
(Patton et al. 1992). Perhaps the best-defined model of immunity of chlamydiae
developed to date is the mouse genital tract infection system using murine or human
isolates of C. trachomatis (Morrison 2000; Patton and Rank 1992). In addition to the
availability of information and reagents for detailed pathologic and immunologic
analyses, the mouse model of chlamydial genital infection exhibits disease patterns that
are similar to human disease (Morrison et al. 2002). The pathologic features include
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chlamydial shedding, uterine and tubal inflammation, and development of complications
such as hydrosalpinx, and tubal factor infertility (Igietseme 2003). Furthermore, the
elements of protective anti-chlamydial immunity identified in mice appear to be relevant
for chlamydial control in humans (Brunham 1999). The mouse model of chlamydial
genital infection has therefore yielded and continues to furnish highly useful pathologic
and host response information in the areas of disease evolution, the essential elements of
protective immunity and the basis for vaccine selection and evaluation that could be
extrapolated to humans.
The immune system maintains a significantly different response to intracellular
and extracellular pathogens (Lagrange et al. 1985, Deshpande et al. 2000). The goal of
the immune response to extracellular pathogens involves eradicating the pathogen itself
and neutralizing its infectious products. Antibodies that are particularly effective against
extracellular pathogens are more complex and involve several options for disease
elimination. An immune response to intracellular invasion should aim to either directly
destroy the infected host cell through cytotoxic mechanisms or should act to activate
infected target cells to destroy the pathogen itself (Patton et al. 1992). Therefore,
clearance of an established intracellular infection involves the elicitation and activation of
T cells and/or natural killer cells, as well as other effectors of T cell-mediated immune
response.
Pathogens, such as C. trachomatis, are controlled by an assortment of immune
effectors. An important element in the development of a reliable prophylaxis to control
Chlamydia, such as a vaccine, is the clarification of immunologic and other factors that
will ensure long-term immunity in order to achieve better vaccine efficacy. The cellular
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immune response to chlamydial infection is characterized by complex interactions
between many different effector cells responding to the pathogen (Igietseme 2002;
Loomis 2002). Chlamydial genital disease initiates at and appears to be confined to the
epithelium of the genital mucosae (Hodinka 1998; van Westereenen et al. 1998).
Specific lymphoepithelial interactions in the genital mucosae are associated with genital
exposure to chlamydiae. These interactions lead to the elicitation of anti-chlamydial
immune responses, with resultant development of specific immunity and resolution of
disease.
A host response to chlamydial infection is two-fold. The host must protect itself
against both the infectious EBs colonizing new cells and those residing in previously
infected cells. Inflammation is the hallmark of chlamydial infection and involves a focal
inflammation marked by high infiltration of polymorphonuclear cells (PMNs or
neutrophils) as an initial immune response. This is followed by mononuclear cells, which
are recruited to the site of infection. Subsequently, specific immune responses involving
T and antibody-secreting B cells are elicited (Loomis 2002; Morrison et al. 2002). Thus,
the profile of immune responses measured following chlamydial infection of humans and
experimental animal models include a strong T cell response characterized by
chlamydial-specific CD4^ and CD8^ T cells, and their cytokines which are induced
following exposure to Chlamydia (Morrison 2000; Igietseme and Rank 1991; Moore et
al. 2002). In addition, humoral immune effectors characterized by activated EB cells,
serum and secretory anti-chlamydial antibodies are elicited during a genital chlamydial
infection (Moore et al. 2002).
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Host immune responses during genital chlamydia infection are directed at
different chlamydial antigens, but the level of contribution of antibodies versus T cells to
chlamydial clearance and establishment of immunity requires clarification in order to
better target vaccines.
Role of Thl Effectors in Chlamydial Clearance and Immunity. Cell mediated immune
response (CMI) involves the induction of T helper type 1 cells (Thl), cytotoxic T
lymphocytes (CTLs) and their cytokines, which are capable of activating other
inflammatory cells such as macrophages, NK cells, and dendritic cells. The CD4^ T
helper cells recognize foreign antigens via a peptide complexed to major
histocompatibility complex class II (MHC II) molecules on dendritic cells, macrophages,
and other antigen-presenting cells. Upon activation, 004"^ T helper cells are the primary
regulators of several T and B cell mediated responses including: 1) providing help for
antigen-stimulation of subsets of B cells to proliferate and produce antibodies ofdifferent
isotypes and 2) activating other effector T cells in cell-mediated immunity (Loomis 2002;
Darville 2006).
CD4'^T cells can be subdivided into different subsets. The differentiation process
is initated by the ligation of the T cell receptor (TCR); and cytokines present during the
initiation of a T cell response determine the development of the particular T helper type 1
(Thl) subset (Bonnechi, 1998). T-helper type 1 cells secrete IL-12, IFN-y and
lymphotoxin, whereas T-helper type 2 (Th2) cells secrete IL-4, -5, and -13. T-helper type
1 cells predominately control cell-mediated immune responses and appear to be involved
in chronic inflammatory conditions, whereas Th2 cells upregulate immunoglobulin E
(IgE) production and are prominent in the pathogenesis of allergic diseases (Bonnechi
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1998). Polarization of the T cell subsets most likely occurs in the secondary lymphoid
organs to which naiVe T cells preferentially migrate. Memory lymphocytes and effector
precursor cells, in contrast, migrate to peripheral tissues. It is likely that, given their
different effector functions, Thl and Th2 cells are differently recruited to peripheral sites
of inflammation (Baggiolini 1997). Indeed, it has been shown that Thl, but not Th2 cells,
express a functional ligand for P- and E-selectin and therefore are selectively recruited to
sites where Thl immune responses occur (Bonecchi et a/. 1998). The lymphocytes
include the B cells, CD4^ and €08"^ T cells (Morrison et al. 2000).
Analyses of hosts antichlamydial immime mechanisms in animal models have
shown that in guinea pigs both humoral and cell mediated immimity are essential for the
resolution of and resistance to infection (Rank et al. 1985). Studies using athymic nude
mice revealed the importance of cell-mediated immunity in protection against chlamydial
genital tract infection. In this study performed by Rank and colleagues (1985), 8 week
old nude mice (nu/nu) and mice heterozygous for the nude trait (+/nu) were inoculated
intravaginally with mouse pneumonitis (MoPn), the heterozygous mice resolved their
infection in 20 days and had an increased titer of immunoglobulin G (IgG) antibody to
MoPn by day 17, whereas the homozygous mice showed a decrease in IgG and
developed chronic infection which lasted 265 days (Rank et al. 1985). Moreover,
adoptive transfer experiments have confirmed the importance of CD4^ T cells in the
clearance ofChlamydia (Ramsey et al. 1991; Su et al. 1995).
In addition to CD4^ T cells, €08"^ cells also contribute to antichlamydial
immunity in vivo (Igietseme et al. 1994). The mouse model demonstrates a subordinate
role for CD8+ T cells in the resolution of genital infection. Mice deficient in P2-
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microglobulin resolve infection as efficiently as wild-type mice (Darville 2006), and mice
deficient in the cytolytic effector molecules, perforin and CD95 (Fas), effectively clear
infection with C. muridarum. However, C. muridarum-s^Qcxfxc CD8^ T cells efficiently
lyse C. /wMriWaru/n-infected cells transfected with intracellular adhesion molecule ICAM-
1, indicating the potential for CD8^ T cells to contribute to the elimination of infection.
Gene knockout studies have indicated that CD8^ and B-cell knockout mice are as potent
as immunocompetent wild-type mice (Johansson et al. 2001, 1997; Morrison et al. 1995;
Su et al. 1995) in the clearance of chlamydia. These results suggest that neither B cells,
antibodies, nor CD8^ T cells contribute exclusively in the clearance of primary
chlamydial infection. In contrast, CD8^ cell deficient mice remain protected from re¬
challenge (Morrison et al. 2000), whereas B-cell deficient mice are susceptible to re¬
infection and exhibit delayed clearance of chlamydiae, suggesting that B cells may play
an important role in resistance to re-infection.
Role of antibodies in induction of protective immunity against C. trachomatis. The
mouse model suggests a lack of importance for B cells or antibody in resolution of
primary genital infection, as B cell deficient mice resolve primary infection normally, and
passive immunization has a minimal effect on the course of primary infection. In the
female guinea pig model of genital infection however, antibody plays an important role in
eradication of infection. Antibody-depleted guinea pigs maintain a high level of primary
infection, and passive immunization of naive animals results in a marked decrease in the
level of primary infection compared with controls. Moreover, Moore et al. (2002)
showed that B cells participate in anti-chlamydial immimity via FcR-mediated effector
function ofantibodies, which are operative during re-infections.
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Antibodies specific for C trachomatis can neutralize infection in tissue culture.
However, high titer of C. trachomatis-specific antibody does not correlate with increased
severity of sequelae, such as tubal factor infertility (TFI) (Morrison 2002). In these
epidemiological studies, high titers of antibody may reflect repeated infection, known to
be associated with increased morbidity. Although antibody may not play a primary role
in resolution of infection, studies suggest it may help control the shedding of organisms
and protect against upper tract disease. One study reported the prevalence of mucosal
IgA antibodies was inversely related to the quantity of C. trachomatis shed from the
human endocervix (Darville 2006), and another found the presence of serum IgA and IgG
antibodies reduced the risk of ascending infection among women undergoing therapeutic
abortion. Ramsey et al. (1988) characterized the humoral immune response to MoPn
genital infection. By enzyme-linked immunosorbent assay, they found that IgG
(Immunoglobulin G) first appeared in the plasma on day 14 and that IgA
(immimoglobulin A) was first detected in vaginal washes on day 21. However it has also
been foimd that mice are capable of resolving MoPn genital infections in the absence of
antibody response (Ramsey et al 1988). Interestingly, it was also observed from a
similar study that mice were susceptible to re-infection, which could possibly mean that
the immune response lowers significantly to allow the establishment of a second
infection. In addition, Igietseme and Rank (1991) concluded that susceptibility to re¬
infection was due to the intensity of the local T cell mediated immune response in the
genital tract.
Role ofCo-Stimulatory and Adhesion Molecules in Chlamydial Clearance and Immunity.
Certain co-stimulatory and adhesion molecules expressed by antigen presenting cells
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(APCs) are important for effective immune activation and maintenance and so their
modulation could lead to up-regulation of the required Thl response during vaccine
delivery against Chlamydia. For instance, dendritic cell (DC) potency as high efficient
APCs is due in part to their high co-stimulatory ability, which is associated with the
elevated density expression of co-stimulators such as the B7, CD40, ICAM-1 and
leukocyte function antigen type-3 (LFA-3) molecules (Jenkins et al. 1993; King et al.
1993). Both co-culture experiments and in vivo work support role for the ICAM-1 in anti-
chlamydial immunity (King 1993). Intracellular adhesion molecule-1 is a cell adhesion
molecule expressed by leukocytes, endothelial and epithelial cells. It is a prominent
member of the immunoglobulin super gene family of proteins that function as adhesions
in host defense and pathology. ICAM-1 plays roles in rapid T cells activation,
recruitment, and retention in the genital mucosa of infected animals by binding with high
affinity to LFA-1 on the surface of T cells. Following binding, ICAM-1 is involved in
signal transduction for lymphocyte activation and function (Freyer 1999). ICAM'^' mice
displayed a delayed Thl response to chlamydial genital infection, severe acute cervical
and ascending infection, and high rates of tubal complications (i.e. hydrosalpinx), which
is associated with a slow activation of specific Thl cells by ICAM-1 APCs (Freyer
1999).
Additional co-stimulatory molecules include CD40, which belong to the TNF-
family of receptor proteins and plays a central role in the effector function of fully
differentiated T cells. CD40 is expressed on APCs and interacts with the CD40 ligand on
the T cell’s surface to contribute to bi-directional signaling, where both the T cell and the
APC receive activating signals (King et al. 1993). CDllc is a component of the
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leukocyte integrin (CD 11 c/CD 18 or CR4) on mature dendritic cells, functioning in
leukocyte adhesion and phagocytic responses (Serre 1998). The co-stimulatory B7
molecules, B7.1 (CD80) and B7.2 (CD86), are members of the immunoglobulin gene
super family of proteins and the principal co-stimulatory molecules expression on APCs.
The homodimers bind to CD28 on the surface of T cells and clonal expansion of T cells
cannot occur until this binding takes place (Jenkins et a/. 1993; King e/a/. 1993). B7.1
(CD80) and B7.2 (CD 86) help CD4^ T precursor cells to mature along two alternative
pathways, Thl and Th2, respectively. On APCs, the interactions of B7.1 and B7.2 have
shown to be reciprocally expressed with the down-regulation of the one leading to
concomitant up-regulation of the other. Interestingly, their roles have been demonstrated
both in vitro and in vivo to be predominant in altering initial cytokine profiles of activated
cells rather than overall cell induction (Kelly and Rank 1997).
Influential factors in the Induction of Protective Immunity
Since it has been established that CMI effectors are required for protective
immunity against genital chlamydia infection, a better understanding of the factors that
influence the generation of optimal T-cell response during infection is important for the
development of an effective vaccine and/or therapeutic agents. In this respect it appears
that factors that may regulate the T cell processes APCs, cytokines/chemokines released
by infected cells, cytokine/chemokine receptors, and the hormonal environment during
infection.
Cvtokine/Cvtokine Receptors. Chemokines, a superfamily of polypeptide
mediators, are a key component of the leukocyte recruitment process (Bonecchi et al.
1998). The relative position of a Cys tandem defines four structural motifs (CXC, CC, C
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and CX3C). Five receptors for CC chemokines (named CCRl through 5) and fom for
CXC (CXCRl through 4) have been defined. Increasing evidence suggests that
chemokines play an important role in the regulation of T-helper type 1 (Thl) and T-
helper type 2 (Th2) responses in vivo. The induction of specific Thl-recruiting
chemokines during primary and secondary genital chlamydial infection has been
established with protective Thl cells recruited to infected genital mucosa more efficiently
under the influence of specific chemokines (i.e. RANTES, MIP-la and MIP-lp) than
non-protective Th2 cells (Kelly and Rank 1997).
Chlamydia infection generates a cytokine response both by direct infection of
epithelial cells lining the moist surfaces of the body and interaction with cells of the
immune system (Fitzpatrick 1991). Infection of epithelial cells derived fi’om human
cervix, a major cause of the genital tract infection generates various cytokines such as
[(interleukin-6 (IL-6); interleukin-8 (IL-8), interleukin-la (IL-la)], (Granulocyte
Macrophage-Colony Stimulating Factor, (GM-CSF). Belay et al. (2002) demonstrated
that after genital chlamydia infection in C57 mice, elevated levels of chemokines
RANTES, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein
la (MIP-la), and gamma-interferon-inducible protein 10 (IP-10) were produced.
RANTES, MCP-1, MIP-la and IP-10 play significant roles in leukocyte activation and
recruitment during Chlamydia infection (Figure 2) These studies were in accord with
other findings by Darville et al. (2001), who examined TNF-a, IL-ip IFN-y, IL-10,
(macrophage inflammatory protein-one alpha) MIP-la, and (monocyte chemoattractant
protein) MCP-1 in various strains of mice (C57BL/6, BALB/c, and C3H). It was
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concluded that there was a prolonged and increased levels of TNF-a, IL-ip, IFN-y and
lower IL-10 response in the C57BL/6 strain compared to BALB/c and C3H. Hence, early
increases in the levels of the pro-inflammatory cytokines were associated with earlier
eradication of infection. Because of the higher Thl response in C57BL/6 mice, they
sustained a shorter course of infection and less oviduct pathology than did the C3H mice
during the first week of infection.
Additional cytokine studies have shown that mice depleted in interleukin-12 (IL-
12) or IFN-y and/or the IFN-y receptor have an inability to clear primary chlamydia
infection (Cotter et al. 1997; Johansson et al. 1997, and Perry et al. 1997). Interferon
gamma has been shown to play a vital role in the clearance of chlamydia. The two IFN-
y-inducible host cell functions that have received the majority of attention in studies of
chlamydia immimity are the induction of inducible nitric oxide synthase (iNOS) and of
tryptophan-decyclizing enzyme indoleamine 2, 3-dioxygenase (Morrison and Caldwell,
2002). To determine the rote of nitric oxide (NO), Igietseme et al. (1998) used iNOS
knockout mice and analyzed the effect of NO on in vivo and in vitro growth of
Chlamydia and reported that the iNOS pathway was not required for elimination of
chlamydia from epithelial cells lining the female genital tract, however NO may control
the dissemination of C. trachomatis by infected macrophages. Indoleamine 2, 3-di¬
oxygenase (IDO) is an enzyme that catalyzes the decyclization of L-tryptophan into N-
formylkynurenine. L-tryptophan is an essential amino acid for chlamydia growth (Byrne,
etal. 1986). Therefore, depletion of L-tryptophan inhibits growth.
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Chlamydia infected mice that were IL-6 and TNF-a receptor deficient and
depleted of TNF-a had minimal or no measurable effect in the ability to resolve primary
infection or resist against secondary challenge (Darville et al. 2000, Perry et al. 1998).
These results demonstrate the importance of Thl immunity in resistance to chlamydial
infection. Moreover, in a study by R. Johnson (2004), it was concluded that a cloned cell
line infected by C muridarum secreted TNF- a, a major activator of neutrophils within
infected tissues. Tumor Necrosis Factor-a, IL-la, and GM-CSF made by epithelial cells
would activate macrophages and trigger dendritic cells maturation. IL-6 is an important
cytokine in cytotoxic T-cell differentiation (Johnson 2004) (Figure 2.) In contrast,
studies investigating Neisseria gonorrhea, a bacterium associated with another well
known STD, gonorrhea, suggested that IL-8, IL-6, and possible tumor necrosis factor
alpha (TNF-a) were produced at the local site of infection.
These cytokine responses appear to be directed by the differential expression of
chemokine receptors on Thl- and Th2- cell subsets (Belay 2002). The identification of
several new chemokines has revealed that chemokines also play an important role
coordinating the movement ofT cells, B cells and dendritic cells necessary to generate an
immune response. Chemokine messages are decoded by specific receptors that initiate
signal transduction events leading to a multitude of cellular responses, leukocyte
chemotaxis and adhesion in particular. Receptor expression in different leukocyte
subsets dictates to a large extent the spectrum of action of chemokines, and
differentiation or cellular activation modulates receptor expression (Baggiolini et al.
1997). Bonecchi et al. (1998) reported that human This and Th2s differentially express
chemokine receptors and, accordingly, differentially migrate in response to different
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chemokines. In addition, this investigator also observed cells bearing the chemokine
receptors chemokine receptor 5 (CCR5) and chemokine receptor 3 CXCR3, which are
known to be expressed on Thl and dendritic cells.
Interestingly, Belay et al. (2002) showed that CCR5 are expressed on the T cells of
mice infected with genital chlamydial infection. Chemokine receptor-5 plays an
important role in various inflammatory diseases, infections and atherosclerosis. Various
studies have indicated that CCR5-deficient mice were significantly more susceptible to
infections with the parasites Listeria monocytogenes. Cryptococcus neoformans and
Toxoplasma gondii (Khan et al. 2006). Moreover, they displayed an increased mortality
in influenza A virus infection. Studies have also shown that CCR5 and CCR2 knockout
mice appear to have a partial defect in macrophage fimction and show a decreased Thl
immune response, as measured by a reduced production of Thl cytokines, such as IFN-y
(Yang et al. 1998; Patton and Rank 1992) and IL-12 (Mack 2001). Mack and colleagues
successfully developed mouse monoclonal antibodies (mAbs) against the murine
chemokine receptor CCR5 and found that the absence of this receptor decreased the
inflammation that is usually observed in inflammatory diseases such as nephritis and
arthritis. R. Gallos (2000) laboratory showed the first clue that chemokine-related events
were important in HIV pathogenesis. Their investigation showed that high levels of
chemokines could inhibit HIV replication in vitro (McNicholl 2003). A cohort of highly
exposed, HIV-negative men had high circulating levels of several chemokines, such as
RANTES, MIP-la, and MIP-ip. This finding led others to conduct studies, which
ultimately concluded that CCR5 plays a pivotal role by acting as a co-receptor with CD4
for the entry ofHIV (McNicholl 2003).
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Chemokine receptor-5 has also been shown to be a critical receptor in guiding
natural killer cells trafficking in host defense. With the influx ofNK cells, tissues from
CCR5-deficient (CCR5-/-) mice were more susceptible to infection with Toxoplasma
gondii infection (Khan et al. 2006). In studying other bacterial infections, it has been
shown by Peters et al. (2001) that CCR2 (chemokine receptor 2), another Thl receptor,
serves an early and essential role in resistance to Mycobacterium tuberculosis.
As a crucial receptor involved in T cell activation and function, a deficiency ofCCR5
is associated with a suppression ofT cell induction and leukocyte migration under certain
infectious and non-infectious conditions, suggesting that it plays a role in both infection-
related immune and inflammatory processes. The effect of a targeted suppression of the
critical specific T cell response on both immune-mediated microbial clearance and the
development of complications ofchlamydial infection is largely unknown.
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Figure 2. Summary ofBml.l 1 oviduct epithelial cell cytokine responses to infection by
C. muridarum. Relative expression levels are reflected by type sizes within the figure,
with 4+ represented by the largest type size [e.g., MARC (CCL7)], 3+ represented by the
second-largest type size (e.g., CXCL16), 2+ represented by the second-smallest type size
(e.g., TNF-o), and 1+ indicated by the smallest type size (e.g., IL-3). PMN,
polymorphonuclear cell; Eos, eosinophil (Johnson et al. 2004)
Hormonal Environment. Estrogens are aromatized steroid hormones synthesized from a
cholesterol backbone and produced predominately in the ovary, although some
aromatization may occur in adipose tissue. Estrogen production increases gradually
throughout female development. Estrogens may occur in many forms: 17-P estradiol is
the most common circulating form. Precursors to estrogen in the steroid biosynthetic
pathway include progesterone, dehydroepiandrosterone (DHEA), and testosterone
(McMurray 2001)
Estrogen modulates lymphoid cell growth and differentiation, proliferation,
antigen presentation, cytokine production, antibody production, cell survival, and
apoptosis (McMurray 2001). Although few studies have dissected direct hormonal
effects on cytokine profiles in human lymphohematopoietic cell subsets, CD4^ T cell
clones from multiple sclerosis (MS) patients have shown cytokine-specific dose-
dependent response to estrogen (Cohen et al. 1983). In addition, progesterone facilitates
production of Th2 cytokines in normal T cell clones (Piccinni et al. 1995). Vassiliaudou
et al. (1999) determined whether progesterone affected mechanisms underlying the
sexual transmission of HIV-1 and observed that hormonal treatment had no effect on
expression of CCR5 and CXCR4 by nonactivated T cells and macrophages, but
significantly inhibited IL-2-induced up-regulation of CCR5 and CXCR4 on activated T
27
cells. In addition, this group also concluded that progesterone inhibited both mitogen-
induced proliferation and chemokine secretion (MIP-la, MIP-1(3, and RANTES) by
CD8+ T lymphocytes.
Epidemiologic evidence suggests that infection with C. trachomatis is enhanced
by oral contraceptives (Washington et al. 1985). This link between hormonal
contraception and cervical infections is biologically plausible because estrogen and
progesterone can enhance or suppress the growth and persistence of vaginal flora. In a
quantitative review by Cottingham and Hunter (1992), it was observed that women who
chose Depo-Provera as a contraceptive experienced a three-fold increase in the risk of
acquiring two of the most commonly spread bacterial STDs; chlamydial and gonorrhea.
Although these findings were interesting, the study did not look into the behavioral
actions that could have attributed to the increased risk.
In vitro studies have shown that treatment of HeLa 229 cultures with 17-P-
estradiol, and a synthetic analog diethylstilbesterol prior to infection with C. trachomatis
serovar K or serovar LI led to a 50 to 60% enhancement of chlamydial inclusion
formation (Bose and Goswami 1986). This enhancement was reversed when cells were
treated with an anti-estrogen tamoxifen.
Sex hormones regulate immune responses in the female reproductive tract. The
estrous cycle and treatment with sex hormones such as estradiol and progesterone, have
been demonstrated to influence mucosal immune elicitation and function in the genital
mucosal surface, cytokine expression and recruitment or trafficking of leukocytes into the
reproductive tract (Jungi et al. 1997; Prabhala et al. 1995). Kaushic et al. (1998) used a
rat model to study the effects of sex hormones on C. trachomatis. It was concluded that
28
enhanced lymphocyte proliferation was observed in response to mitogenic and MOMP
stimulation in the reproductive tract-draining lymph node (LN) from estrous and
diestrous animals. In addition, it has also been noted that pre-treating guinea pigs with 17
P-estradiol prior to infection enhanced the course of infection of guinea pig GPIC (Rank
et al. 1982). These findings are comparable to others stating that estrogen’s effect on
vaginal candidiasis and N. gonorrhea. The incidence of vaginal candidiasis increases
with the use of oral contraceptives (Washington 1985). Mice are more susceptible to
genital infection with N. gonorrhea at proestrus, when estrogen levels are higher (Kita et
al. 1981).
Although, there is supporting evidence that sex hormones have an effect on
bacterial infection, the cellular, and molecular and biochemical mechanisms underlying
this influence on genital infections by specific microbial pathogens have not been clearly
identified (Sonnex et al. 1998).
The scope of this work was to investigate estrogen’s effect on the induction of





Inbred, chemokine receptor-5 KO (CCR5‘^‘), and wild type female mice, 5-8 week
old, were purchased for these studies.
Mouse Strain Knockout gene Designation Source
C57BL CCR5-/- CCR5 KO Jackson Laboratory
(Bar Harbor, ME)
All animals were housed in the animal facility of the Atlanta University Center (AUC),
located at Morehouse School of Medicine (Atlanta, GA). Animals were fed food and
water ad libitum, and maintained in laminar flow racks under pathogen-free conditions
(Trexler germ-free isolators) of 12-hr light and 12-hr darkness. Supervision of animal
care was under a licensed veterinarian and a qualified manager, Mr. Clarence Wilkes
(Morehouse School ofMedicine, Atlanta, GA).
Antigen
Stocks of the Chlamydia trachomatis agent of mouse pneumonitis (C.
muridarumlMoPr^ were generously provided by Drs. Joseph Igietseme and Carolyn




McCoy This is a murine fibroblast cell line that has been used to propagate
laboratory strains of all recognized C. trachomatis serotypes (Hodinka et al. 1998)
designated American Tissue Cells Culture (ATCC) CRT-1696. Cells were purchased
from ATCC (Manassas, VA).
HeLa This is an epithelial-like cell line derived from human cervical carcinoma
tissue, designated at ATCC CCL-2, and was purchased from ATCC. HeLa cells have
been found to efficiently support the growth ofMoPn in culture.
Tissue Culture Reagents andMaterials
Cvcloheximide Medium (CXT Sterile, filtered complete CX medium contained
10% Fetal Bovine Serum (FBS) (heat inactivated at 56 °C for 30 minutes) (Atlanta
Biological, Norcross, GA), 3 mg/ml of glucose (Atlanta Biological, Norcross, GA), 100
pg/ml of vancomycin (Dr. Joseph Igietseme, MSM, Atlanta, GA), 100 pg/ml of
gentamycin (Atlanta Biological, Norcross, GA), 1.25 pg/ml of fungizone (Atlanta
Biological, Norcross, GA), and 0.5 pg/ml of cycloheximide (Sigma, St. Louis, MO) in
Dulbecco’s modified eagle medium (DMEM, Atlanta Biological, Norcross, GA). Media
was stored at 4°C until use.
Complete Dulbecco’s Modified Eagle Medium (DMEML Sterile, filtered
complete DMEM contained lOOmM sodium pyruvate (Atlanta Biological, Norcross,
GA), 10 mM non-essential amino acids (Atlanta Biological, Norcross, GA), IM HEPES
(Atlanta Biological, Norcross, GA), lOOX insulin/transferring/selenium (ITS, Dr. Carolyn
Black, CDC, Atlanta, GA), 100 mM L-glutamine (Atlanta Biological, Norcross, GA), 50
mg/ml gentamycin (Atlanta Biological, Norcross, GA), 240 pg/ml
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fungizone/amphotericin B (Atlanta Biological, Norcross, GA) and 10% fetal bovine
serum (heat inactivated at 56 °C for 30 minutes, Atlanta Biological, Norcross, GA) in
Dulbecco’s modified eagle medium (DMEM, Atlanta Biological, Norcross, GA). Media
was stored at 4 °C until use.
Transport Medium. Sterile, filtered transport medium contained 50 mg/ml
gentamycine (Atlanta Biological, Norcross, GA), 250 pg/ml fungzone/amphotericin B
(Atlanta Biological, Norcross, GA), 10% FBS (heat inactivated at 56 °C for 30 minutes;
Atlanta Biological, Norcross, GA), 100 pg/ml vancomycin (Dr. Joseph Igietseme, MSM,
Atlantal, GA) and 2-SP buffer (prepared in the laboratory-see methods). Media was
stored at 4 °C until use.
Roswell Park Memorial Institue (RPMB Complete Medium. Sterile, filtered
RPMI complete medium contained RPMI-1640 (Atlanta Biological, Norcross, GA) with
10% FBS (Atlanta Biological, Norcross, GA), 100 mM sodium pyruvate (Atlanta
Biological, Norcross, GA), HEPES (Atlanta Biological, Norcross, GA), 200 mM L-
glutamine (Atlanta Biological, Norcross, GA), 1 M Penicillin-Streptomycin (Pen-Strep,
Atlanta Biological, Norcross, GA), and 1 ;200 dilution of 55 mM 2-mercaptoethanol (2-
ME, Gibco BRL, Life Technologies, Gaithersburg, MD) diluted in RPMI-1640. Media
was stored 4 °C until use.
RPMI Complete Medium without Penicillan-Streptomvcin (Pen-Strep). Sterile,
filtered RPMI complete medium contained RPMI-1640 (Atlanta Biological, Norcross,
GA) with 10% FBS (Atlanta Biological, Norcross, GA), 100 mM sodium pyruvate
(Atlanta Biological, Norcross, GA), 10 mM non-essential amino acids (Atlanta
Biological, Norcross, GA) IM HEPES (Atlanta Biological, Norcross, GA), 200 mM L-
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glutamine (Atlanta Biological, Norcross, GA), 50 mg/ml gentamycin (Atlanta Biological,
Norcross, GA) and 1:200 dilution of 55 mM 2-mercaptoethanol (2-ME, Gibco BRL, Life
Technologies, Gaithersburg, MD) diluted in RPMI-1640. Media was stored at 4 °C until
use.
Tissue Culture Flasks and Plates. 75 cm and 150 cm flasks and 60 x 15 mM
plastic Petri dishes were purchased from Coming Costar Corporation (Cambridge, MA).
Tissue culture plates (i.e. 6-, 24-, 96-well flat and round-bottom plates) were purchased
from Coming (Coming, NY).
Other Reagents andMaterials
Phosphate-Buffered Saline rPBST Sterile, filtered IX PBS (pH. 7.4) contained 8
g of NaCL (Gibco, BRL, Life Technologies, Gaithersburg, MD), 0.2 g of KCL (Fisher
Scientific, Pittsburgh, PA), 1.15 g of Na2HP04 (Fisher Scientific, Pittsburgh, PA), and
0.2 g of KH2PO4 (Fisher Scientific, Pittsburgh, PA) in 1 liter of dH20. PBS was stored at
4 °C until use.
Lysing Buffer. Tris-Ammonium Chloride (NH4CI) (pH. 7.2) contained 7.5 g
NH4CI (Fisher Scientific, Pittsburgh, PA) and 2.05 g of Tris (Fisher Scientific,
Pittsburgh, PA) in 1 liter of dH20. The lysing buffer was used to remove red blood cells
from leukocyte preparations according to a previously described procedure (Moore
2002). The pH was adjusted to 7.2 and the solution was stored at 4 °C until use.
Trypan Blue. Trypan Blue at a concentration of 0.4% prepared in 0.85% saline
solution (Gibco BRL, Life Technologies, Gaithersburg, MD) was used to detect cell
viability.
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Enzyme-Linked Immunosorbent Assay (ELISA) Reagents. ELISA kits for
quantitating the amounts of murine cytokines in biological and culture fluids were
purchased from BioSource International (Camarillo, CA). All necessary assay
components (i.e. 1®* and 2"'* antibodies, blocking reagents and washing buffer) were
supplied with each indiyidual kit and used according to the manufacturer’s protocol.
Instrumentation
Fluorescent Microscope. Zeiss (Zeiss, Atlanta, GA) fluorescent microscope was
used for the immunofluorescence yisualization and enumeration ofchlamydial inclusions.
Hemacytometer. Bright line hemacytometer (Hausser Scientific, Horsham, PA)
0.1 mm deep, was used to enumerate yiable cells using the trypan blue exclusion method.
Incubator. NuAire™ IR Autoflow CO2 Water-Jacketed Incubator (Med-Rep Inc.,
Newnan, GA) was used to incubate cell and tissue cultures at 37°C and 5% CO2.
Gamma-Irradiator. Gammacell 1000 EliteTM gamma-irradiator (Nordion
International, Inc., Kanata, Canada) was graciously made ayailable through the laboratory
of Dr. Godwin Ananaba (Clark Atlanta Uniyersity, Atlanta, GA) to irradiate murine
spleen cells.
Spectrophotometer. Gene Quant II ™ (Amersham Pharmacia Biotech,
Piscataway, NJ) was used to quantify RNA absorbance leyels in cell culture samples.
Centrifugation. Marathon 12 KBR Centrifuge (Fisher Scientific, Pittsburgh, PA)
and Eppendorf Centrifuge 5402 (Brinkman Scientific, Westbury, NY) were used
throughout experimentation.
34
Micro-Titer Plate Reader. Molecular Devices SpectraMax 250™ (Sunnyvale,
CA) was used to quantify murine cytokine levels elaborated by biological and culture
fluids during ELISA experiments.
Methods
Animal Development
Chemokine Receptor-5 Knockout Mice (CCRSKOL CCR5KO mice (C57BL/6
background) were developed by gene targeting inactivation in the laboratory. CCR5 is a
seven transmembrane-spanning G-protein-coupled-receptor. It is expressed in lymphoid
organs such as thymus and spleen and on monocytes, macrophages, T-cells and B-cells.
Zhou et. al. have generated mice lacking expression of CCR5. These mice develop
normally in a pathogen-free environment, but show reduced efficiency in clearance of
Listeria infection.
Chlamydial Stock andAntigen Preparation
Stocks of the Chlamydia trachomatis of mouse pneumonitis (C.
muridarum/MoPn) were prepared by propagating elementary bodies (EBs) in McCoy
cells (Ramsey et al. 1988). Briefly, MoPn was cultured in McCoy cells in DMEM
containing 10% FBS (see materials). MoPn grown in McCoy cells was stored at -80°C
and thawed just before use. The cell suspension was sonicated and centrifuged at 192 x g
for 10 minutes at 4 °C. The pellet was then suspended in sucrose-potassium glutamate
buffer (pH 7.2).
Stocks were titrated by infecting McCoy cells with varying dilutions of EBs. To
summarize, a 96-well flat bottom tissue culture plate (Coming, Coming New York)
containing 200,000 McCoy cells/well was incubated at 37 °C (5%/C02) overnight to
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produce a monolayer. The following day, serial dilutions (i.e. lO”^, 10'^, and 10'^) of
Chlamydia stock in CX media were added to each well. Wells containing CX media
alone were used as controls. Plates were centrifuged at 3000 rpm for one hour at 34 “C.
After centrifugation, plates were incubated for 2 hours at 37 °C (5% CO2). Afterwards,
medium was aspirated from each well using disposable borosilicate glass pasteur pipet
(Fisher Scientific, Pittsburgh, PA) and fresh, warm CX medium was added to each well.
Plates were incubated further at 37 °C, 5% CO2 for 32 hours. Following incubation,
plates were fixed with methanol (histological grade, Fisher Scientific, Pittsburgh, PA)
and stained with 1:1 dilution in sterile PBS of FITC-conjugated anti-chlamydial
antibodies (PathoDx Chlamydia Culture Confirmation Kit, Diagnostic Products
Corporation, Los Angeles, CA). Inclusions were visualized and enumerated by
immunofluorescence (Ramsey et al. 1988). The infectious titer was expressed as
inclusion-forming units per milliliter (IFU/ml). Chlamydial antigen was prepared by
growing MoPn in HeLa cells and purifying EBs over a renograffin gradient, followed by
inactivation under ultraviolet light for 3 hours.
Intravaginal Inoculation ofMice
Depo-Provera Treatment. Seven days prior to intravaginal infection, mice were
given a single subcutaneous injection of 0.1 ml of a 1:16 dilution (25 mg/ml) of Depo-
Provera (6-alpha-methyl-17-alphahydroxy progesterone acetate. Sigma, St. Louis, MO)
in phosphate buffered saline (PBS). Depo-Provera is a progesterone derivative that
stimulates the negative feedback center of the hypothalamus and inhibits the release of
gonadotropin-releasing hormone (GnRH). GnRH acts on the anterior pituitary to induce
follicle-stimulating hormone (FSH) and lutenizing hormone (LH) secretion. FSH induces
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growth of follicles and follicular estrogen production. Thus, Depo-Provera drives mice to
anestrus enabling the estrous cycle to be halted long enough for productive chlamydial
genital infection to be established. The applied dosage had been found to last
approximately 20 days (Tuffrey et. al. 1986; 1984).
A solution of Depo-Provera was prepared by adding 250 mg of Depo-Provera to
10 ml of filter-sterilized PBS in a 15 ml disposable polypropylene Fisherbrand tube with
a plug seal cap (Fisher Scientific, Pittsburgh, PA). The solution was placed in a 37 °C
water bath for 10 minutes, followed by syringe filtering with a 3 cc syringe (Becton
Dickinson & Co., Franklin Lakes, NJ) with a Precision Glide 30 Gl/2 needle (Becton
Dickinson &. Co., Franklin Lakes, NJ). Depo-Provera was administered through
subcutaneous injection in the vaginal region of the mouse.
Anesthetizing Mice for Intravaeinal Inoculation. On the day of infection, mice
were anesthetized with 0.1 ml of a 1:10 dilution of 50 mg/ml Nembutal (Sodium
Phenobarbital) provided by Dr. Joseph Igietseme, (Morehouse School of Medicine,
Atlanta, GA) in sterile filtered PBS. Nembutal was syringe filtered before use. A 1 ml
latex free syringe (Becton Dickinson & Co., Franklin Lakes, NJ) with a Precision Glide
30G V2 needle (Becton Dickinson & Co., Franklin Lakes, NJ), was used to administer the
intraperitoneal injection. Mice were completely anesthetized before inoculation
occurred.
Infection Protocol. Mice were individually infected with 30 pi of PBS containing
107 IFU/ml of the C. trachomatis agent ofmouse pneumonitis {Chlamydia muridarum or
MoPn). A Clay Adams P200 pipetman (Becton Dickinson& Co., Franklin Lakes NJ and
Clay Adams siliconized micro-selectapette pipette tips (Becton Dickinson & Co.,
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Franklin Lakes, NJ) were used to for intravaginal inoculation of mice. Mice were then
placed on their backs within their respective cages until anesthesia wore off. The mice
were checked 3 hrs after infection for possible adverse reaction(s).
The course of infection was monitored by cervical-vaginal swabbing, every three
days for six weeks, a time period that has been found to span the course of C. trachomatis
genital infection in mice (Patton and Rank 1992; Rank 1999; Khamesipour et al. 1994;
Igietseme and Rank 1991). Mice were swabbed for isolation of chlamydiae from the
vaginal vault and sacrificed to obtain the spleen and genital tract. Experiments were
repeated to give 10 to 12 animals per experimental group.
Isolation ofChlamydia
Cervical-vaginal Swabbing of Murine Genital Tract for Isolation of Chlamdvia.
Chlamydiae were isolated from mice by cervical-vaginal swabbing using individually
wrapped sterile calcium alginate tipped aluminum applicator swabs (Fisher Scientific,
Pittsburgh, PA). Swabs were maintained in sterile, filtered transport medium (see
materials). One milliliter of transport medium was added to labeled, autoclaved 16x10
mm borosilicate screw-top glass tubes (Kimble, Fisher Scientific, Pittsburgh, PA).
Sterile forceps were used to add two autoclaved 6 mm glass beads (Fisher Scientific,
Pittsburgh, PA) to each tube. Tubes were stored at 4 °C until use. Tubes were placed on
ice while individual mice were obtained from designated cages and the genital region was
swabbed vigorously for 30 seconds. Swabs were stored at -80 °C until processed.
Tissue Culture Preparation. Chlamydia was isolated from swabs into tissue culture.
McCoy or HeLa cells were grown and maintained in complete DMEM. Cells in a
confluent monolayer were trypsinized using 0.25% trypsin to detach them from the tissue
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culture flasks and centrifuged at 1230 rpm for 30 minutes at 4 °C in 50 ml Fisherbrand
tubes (Fisher Scientific, Pittsburgh, PA). Following centrifugation, cells were re¬
suspended in complete DMEM and counted using a bright-line hemacytometer (Hausser
Scientific, Horsham, PA) (see materials). Cells (10^) were plated in DMEM in tissue
culture-treated polystyrene sterile non-pyrogenic 96-well flat bottom plates.
Isolation from Genital Swabs into Tissue Culture. Following the preparation of a
confluent cell monolayer, frozen (-80 °C) genital swabs were placed in 1 ml of warm
cyclohexamide (CX) complete medium and vortexed vigorously for 2 minutes to allow
detachment of chlamydiae from the swabs. Two hundred microliters of the CX
suspension containing chlamydiae was added to the cell monolayer in triplicates.
Tissue culture plates containing the genital swab supernatants were centrifuged at
3000 rpm for 1 hour at 34 ®C. Following centrifugation, plates were incubated at 37 °C
(5% CO2) for 2 hours. CX medium was then aspirated from the plates and 200 pi of
fresh CX medium was added. Plates were incubated for an additional 32 hours at 37 °C
(5% CO2). Once the incubation period had expired, plates were removed from the
incubator and the CX media was aspirated from the plates. Sterile 100% methanol (200
pl) was added to each well and plates were placed in either 4 °C for 5 hours or at room
temperature for 2 hours to allow fixation to occur. Afterwards, methanol was removed
from plates by inversion, followed by washing with sterile PBS.
Thirty microliters of fluorescein isothiocynate (FITC)-labeled, genus-specific
purified murine monoclonal antibodies (1:1 dilution of PBS, Chlamydia culture
confirmation kit, PathoDx™, Diagnostic Products Corporation, Los Angeles, CA) were
added to each well of the methanol-fixed tissue culture plates. Plates were allowed to
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stand at room temperature in the dark for 1 hour. To remove the non-binding stain, plates
were washed twice with sterile PBS. Following the wash, plates were inverted into
absorbent paper, covered with aluminum foil and left overnight to allow for removal of
PBS. The following day, one drop of glycerol (90% in PBS) was added to each well.
Plates could then be viewed and chlamydial inclusions would be enumerated using a
fluorescent microscope (Ramsey et al. 1986). For each well, aminimum of 10 fields was
counted, and the average number of inclusions was recorded.
Cell Population Preparations
Preparation of Splenic T lymphocytes. Spleen cells were enriched for T cells by
the nylon wool adherence method (Igietseme et al. 1993). Naive or immunized mice
were sacrificed by cervical dislocation and the entire body cleansed with 70% ethanol.
The spleens were aseptically removed and placed into RPMI 1640 medium with 5% FBS
and 1% HEPES. Isolated spleens were teased with sterile forceps to remove large tissue
clumps. Cell suspensions were treated with lysing buffer for 5 minutes at 37 °C. Cells
were then washed three times by centrifugation at 1300 rpm for 25 minutes at 25 "C.
Following the final wash, cells were re-suspended in 3 ml of RPMI complete medium
(without pen-strep) and run twice through a nylon wool column using warm RPMI
complete medium.
Nylon wool columns were pre-treated the day of use by calibration with RPMI
with 5% FBS and 1% HEPES complete medium. Columns were then incubated for 45
minutes at 37 °C. Splenic cells suspensions were run through a 20 G1/2 needle placed
into a stopcock on a 20 cc syringe. Following, nylon wool extraction, spenic T cells were
centrifuged at 1300 rpm for 40 minutes at 25 °C. Cells were re-suspended in 5 ml RPMI
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complete medium (no pen-strep), enumerated using a hemacytometer and ready for
experimental use. Purified splenic cells contained at least 90% CD4^ cells as was
determined by FACS analysis (Moore et al. 2002)
Preparation of Splenic Antigen Presenting Cells. Naive mice were sacrificed by
cervical dislocation and the entire body cleansed with 70% ethanol. The spleens were
removed surgically using aseptic techniques into RPMI 1640 medium with 5% FBS and
1% HEPES. Isolated spleens were teased with sterile forceps to remove large tissue
clumps. Cell suspensions were treated with lysing buffer for 5 minutes at 37 °C. Cells
were washed three times by centrifugation at 1300 rpm for 25 minutes at 25 °C.
Following the last wash, cells were re-suspended in 3 mis of RPMI complete medium
(without pen-strep) and gamma-irradiated (Gammacell 1000 ElilteTM gamma irradiator,
see materials). Following gamma-irradiation, splenic antigen presenting cells were
centrifuged at 1300 rpm for 40 minutes at 25 °C. Cells were re-suspended in 5 ml of
RPMI complete medium (no pen-strep) and enumerated using a hemacytometer.
Isolation, Reverse Transcription, Real-Time Polymerase Chain Reaction (RT-PCR) in
Estrogen Treated and UntreatedMcCoy cells.
Ribonucleic Acid (RNAl Isolation. Total RNA was extracted from Mopn-infected
McCoy cells that were pretreated with 17 P-estradiol using RNeasy manufacturer’s
protocol (Qiagen, CA). Briefly, Cells were lyzed using Buffer RLT (contains guanidine
thiocyanate). Lysate was pipetted directly into a QIAshredder spin column (supplied by
the manufacturer) and centrifuged for 2 minutes. One volume of 70% ethanol was added
to the homogenized lysate, and mixed well by pipetting. The sample was transferred to
an RNeasy spin column (supplied by manufacturer) and placed in 2 ml collection tube.
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The tubes were centrifuged for 15 s at > 10,000 rpm. Buffer RWl was added to RNeasy
spin column (700 pi) and centrifuged for 15 s at > 10,000 rpm to wash the spin column
membrane. Buffer RPE was added to the spin column and centrifuged for 15 s to wash
the spin column. The RNeasy spin column was placed in a new 1.5 column tube.
RNase-free water was added directly to the spin column membrane and column was
centrifuged for 1 min > 10,000 rpm to elute RNA. Total RNA isolated was quantified by
measuring absorbance at 260 nm and 280 nm. The RNA samples were aliquoted into 5
pg aliquots and stored at -80 °C.
Reverse Transcription of Purified RNA to Complementary Deoxvnucleic Acid
(cDNAT Isolated RNA was used for first strand synthesis using JumpStart AccuTaq™
LA DNA Polymerase Mix (Sigma, St. Louis MO). Briefly, one microliter of random
nanomers (2.5 pM) was added to a tube containing 5 pg RNA and deoxynucleotide mix
(500 uM dNTP) was added to 5 ul ofPCR reagent water to give 10 pi total volume. The
mixture was briefly centrifuged and placed in a 70 °C water bath for 10 minutes.
Following incubation, the tube was placed on ice. The following reagents were added:
PCR reagent water (6pl), lOX buffer for AMV-RT (2pl), RNase inhibitor (Ipl),
enhanced avian RT (Ipl) and reaction tubes incubated at 25 °C for 15 minutes. Reaction
tubes were placed at 50 °C for 50 minutes. The first strand of cDNA was placed at 20 °C
for subsequent PCR amplication.
PCR Amplification of Target cDNA, To amplify mouse cDNA, custom-made
primers were used (Table 1, Invitrogen, California). PCR amplification was carried out
in a Perkin-Elmer DNA Gene AMP 2400 thermocycler. Each tube contained a total
volume of 50 ul: 5 pi of cDNA from RT reaction, 5 pi 1 OX AccuTaq buffer (IX), 1 pi
42
dNTP (200uM), 2 fil JumpStart AccuTaq LA DNA polymerase mix (0.05 imits/ pi) and
0.4 pM of primer (forward and reverse). Sterile water was used to adjust the volume in
thin-walled reaction tubes. Conditions for DNA amplifications were set as follows:
heating at 94 °C for 3 minutes followed by 35 cycles of DNA denaturing for 94 °C for 1
minute, annealing at 58 °C for 1 minute, an extension at 72 °C for 1 minute with a final
extension step at 72 °C for 10 minutes. Equivalent amounts of cDNA template were used
in reactions with primers specific for P-actin, as well as negative controls containing no
cDNA.
Ten microliters of each PCR product was combined with 2 pi of loading buffer
(5X) and 2 pi of sterile water and electrophoresed on a 1% agarose (Sigma, CA) gel
containing 0.5 pg/ml ethidium bromide (Sigma, St. Louis, MO) in IX Tris-
Acetate/EDTA buffer (TAE, Gibco BRL, Grand Island, NY).
Quantitative PCR SYBR Green ReadyMix for High Throughput Quantitative
PCR was used to measure mRNA expression. The following was added to a thin-walled
PCR tube: 25 pi SYBR Green ReadyMix (20 mM Tris-Hydrochloric Acid), pH. 8.3, 25
°C, 100 mM Postassium Chloride (KCL), 7 mM Magnesium Chloride (MgCL2), 0.4 mM
each dNTP, stabilizers, 0.05 unit/ul Taq DNA Polymerase, Jumpstart Taq antibody, 2X
internal reference dye and SYBR Green I), 1 pi primers, 0.2 pM (forward and reverse), 2
pi cDNA and brought up to 25 pi with PCR reagent water. Reaction tube was gently
vortexed and centrifuged. Conditions for DNA amplification were set as follows: initial
denaturation at 95 °C for 2 minutes followed by 35 cycles of DNA denaturation at 95 “C
for 1 minute, annealing at 55 °C for 30 seconds, an extension at 72 °C for 1 minute with a
final extension step at 72 °C for 2 minutes.
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Assay Design
The Effects ofEstrogen on the Expression ofChemokines andAdhesion Molecules during
Chlamydia Infection ofEpithelial Cells
Assessment ofEstrogen’s Effect on Chlamydial growth in Mouse Epithelial Cells.
McCoy cells were grown to 70% confluency in complete DMEM. Once cells reached
confluency, regular DMEM was removed and replaced with phenol-red free DMEM
containing 10% charcoal-dextran treated FBS. After 24 hours, cells were treated with
various molar concentrations of 17 P-estradiol (10‘*, 10'^, 10'**). Estrogen treated cells
were incubated at 37 °C with 5% CO2 for 24 hours. Post incubation, cells were infected
with MoPn. Following 32 hours, media was removed and cells were assessed for
chlamydia infection using immunofluorescence (see methods).
Assessment of Estrogen’s Effect on Chemokine Production in Mouse Epithelial
Cells during Chlamydia Infection. McCoy cells were grown to 70% confluency in
complete DMEM. Once cells reached confluency, DMEM was removed and replaced
with phenol-red fi-ee DMEM containing 10% charcoal-dextran treated FBS. After 24
hours, cells were treated with various molar concentrations of 17P-estradiol (10 *, lO'^,
10 **). Estrogen treated cells incubated at 37 °C with 5% CO2 for 24 hours. Post
incubation, cells were infected with MoPn. Following 32 hours, supernatants were
collected from cells and assessed for chemokine (RANTES, MIP-la, MIP-ip, IP-10,
MCP-1) profiles using ELISA (see methods). Experiments were repeated three times.
To determine mRNA expression RNA was collected from treated and infected
cells and RT-PCR was performed according to methods described above.
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Determination of the Effects of Estrogen on Chlamydia infectivity and
Chemokine/Cytokine Production in a Mouse Model
In Vitro Infectivity Assay to Quantitate Chlamydial Shedding in Vaginal Washes
Estrogen (17 P-estradiol: Sigma Chemical Co, St. Louis MO, dissolved in absolute
Q
ethanol at a concentration of 0.01 M and diluted in saline, 10' M) was administered to
mice intramuscularly for 7 consecutive days. At day 7 mice were infected intra-vaginally
with 10^ IFU of MoPn per mouse. Control mice received saline only. The course of
infection was followed up to five weeks. Chlamydiae were isolated from the swabs in
tissue culture and enumerated by immunofluorescence. The results were repeated to
include 10-12 animals per group.
Chlamydia-induced cell activation, cytokine and chemokine secretion bv
leukocytes. At various times post infection (7, 14, 21 and 38 days) mice were sacrificed
by cervical dislocation. The spleen and genital tracts were harvested and placed in RPMI
(5% FBS, 1% HEPES) and stored on ice until further use. The genital tracts were
homogenized, and T cells isolated by the nylon wool method. The homogenate
containing lymphocytes was stimulated with UV inactivated antigen and APCs for
approximately 5 days. After 5 days the supernatants were collected and analyzed for
chemokines and cytokines (RANTES, MIP-la, MIP-lp, IP-10, KC, IL-4, IL-10, TNF-a,
IL-lp, IL-6 and IL-8) using ELISA as described earlier. The Thl response was measured
by isolating the T cells from the spleen harvested from the estrogen treated and
chlamydia infected animals using the nylon wood method. The isolated T cells were
stimulated with APCs from infected WT mice (2 x 10^ cells/well) and UV-inactivated
antigen (10 pg/ml). After a five day incubation at 37 °C (5% CO2), the supernatants were
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assayed for IFN-y by quantitative ELISA. The concentration of the cytokine and
chemokines in each was obtained by extrapolation from a standard calibration curve
generated simultaneously. Data were calculated as the mean values (± standard
deviation) of triplicate cultures for each experiment. The results were derived from at
least 3 independent experiments.
Evaluation of Estrogen on fertility during chlamydia infection. Estrogen (17 P-
estradiol: Sigma Chemical Co, St. Louis MO, dissolved in absolute ethanol at a
concentration of 0.01 M and diluted in saline, 10'* M) was administered to mice
intramuscularly for 7 consecutive days. At day 7 mice were infected intra-vaginally with
•j
10 IFU ofMoPn per mouse. Control mice received saline only. Two and five weeks
post-infection, groups of animals were mated with male counterparts by placing 3
females to 1 male, and subsequently observed and weighed daily for 19 days to determine
pregnancy, as previously described (Barr et al. 2005). The numbers of pregnant mice in
the different groups were enumerated after 19 days in each case.
Assessment ofChemokine Receptor-5 deficiency on the Infection and Immune Response
during Chlamydia Infection.
In Vitro Infectivitv Assay to Quantitate Chlamydial Shedding in Vaginal Washes
in CCR5 deficient mice. Chemokine receptor-5 deficient mice were treated with depo-
provera (25 mg/ml) seven days prior to infection to stabilize the estrus cycle. Following
depo-provera treatment, mice were infected intra-vaginally with MoPn (lO’ IFU/mouse).
Control mice received saline only. The course of infection was followed up to five
weeks. Chlamydiae were isolated from the swabs in tissue culture and enumerated by
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immunofluorescence according to methods described earlier. The results were repeated
to include 10-12 animals per group.
Chlamvdia-induced cell activation, cytokine and chemokine secretion by
leukocytes. The profile of cytokines and chemokines secreted by leukocytes from
chlamydial-infected CCR5KO and W/T mice was compared by measuring the levels of
specific cytokines and chemokines released following in vitro re-stimulation of the total
splenic cells with UV-inactivated chlamydiae. CCR5KO and control mice were
intravaginally infected with MoPn as described above and at various times post-infection
(7, 14, 21, and 28 days) splenic cells were isolated from infected mice and 2 x 10^ cells
were stimulated with chlamydial antigen (10 pg/ml) and incubated at 37 °C in 5% CO2
for 120 h. At the end of the incubation period, the supernatants were collected and
assayed for cytokines, IFN-y, IL-4, IL-10, TNF-a, IL-lp, IL-6 and IL-8) and Thl
chemokines (RANTES, MIP-la, MIP-ip, IP-10) using a quantitative ELISA. The
concentration of the cytokine and chemokines in each was obtained by extrapolation from
a standard calibration curve generated simultaneously. Data were calculated as the mean
values (± standard deviation) of triplicate cultures for each experiment. The results were
derived from at least 3 independent experiments.
Evaluation of CCR5 deficiency on fertility during chlamydia infection.
Chemokine receptor-5 deficient female mice and wild type mice were infected with 10^
IFU/mouse with MoPn. Two and five weeks post-infection, groups of animals were
mated with male counterparts by placing 3 females to 1 male, and subsequently observed
and weighed daily for 19 days to determine pregnancy, as previously described (Barr et
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al. 2005). The numbers of pregnant mice in the different groups were enumerated after
19 days in each case.
Data Analysis. Quantitative data (IFUs/ml), ELISA cytokine levels, optical
densities, etc.) and non-quantitative (positive and negatives) were processed and
statistically analyzed where applicable. Statistical tests peformed include Fisher’s exact
test and student’s t test (one and two-tailed). The relationship between different
experimental groupings was assessed by analysis of variance (ANOVA). These were all
available through SigmaStat statistical software (SigmaStat, San Jose, CA). Minimal
statistical significance was judged dXp< .05.
CHAPTER 4
RESULTS
The challenge to develop an efficacious vaccine for controlling genital chlamydia
infections requires significant advances in several key areas of immunobiology during
chlamydial infection. For instance, the understanding of immune effectors that assist in
pathogen clearance and identification of factors capable of optimizing genital mucosa
immune responses against an infection are needed (Igietseme et al. 2002). A robust and
sustained T helper type I (Thl) response is considered necessary for the clearance and
long term protection against genital chlamydia infection. Therefore, it is imperative to
understand those factors that may act as immunosuppressors, thereby affecting the Thl
response during infection. Estrogen and chemokine receptors may play a vital role in the
activation and migration of T cells to the site of infection. However, the cellular and
molecular basis of these regulatory functions remains questionable. The goal of these
studies was to evaluate the role of estrogen (17P-estradiol) and chemokine receptor 5
(CCR5) on the induction of protective immunity during Chlamydial infection. Using a
reliable in vitro and murine model of chlamydial genital infection, genetically engineered
specific gene knockout mice, and molecular, immunological, biochemical techniques the
following study objectives included: 1) Assessing the effect of estrogen on infectivity and
chemokine production in an in-vitro system; 2) Evaluating estrogen’s effect on the course
of infection and the induction of the protective immune response in a murine model; 3)
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Investigating the importance of CCR5 in protective immunity during Chlamydia
infection; and; 4) Assessing the role ofCCR5 in pathogenesis during chlamydia infection
as it relates to fertility. The results obtained are exciting and revealing, with crucial
findings and paradigm shifts that are likely to enhance vaccine design against C.
trachomatis and as well as other intracellular pathogens.
Evidence that Estrogen influences Chlamydial Infection and Immunomodulatory
Molecules in a Murine In Vitro System
Estrogen increases chlamydial infectivitv in murine epithelial cells. Studies have shown
that estrogen may increase host susceptibility to chlamydia infection. It was
hypothesized that estrogen pre-treatment would enhance chlamydia infectivity in
epithelial cells. McCoy cells were pretreated with 17 P-estradiol (lO'^M) 24 hours prior
to MoPn infection (10^ IFU/ml). Results in Figure 3 show that there was a significantly
higher number of fluorescent inclusion forming units (IFU/ml) observed in the estrogen
treated cells compared to the untreated (logio3 versus logiol ; p< 0.01) cells.
Figure 4 is a visual representation of the inclusion body containing cells. Panel A
represents cells without estrogen or Chlamydia; Panel B represents cells that were not
treated with estrogen prior to infection. Panel C represents cells that were pretreated with
estrogen and infected with MoPn 24 hours following estrogen treatment. There was a
higher number of inclusion bodies observed in the estrogen treated/chlamydia infected
cells (Panel C) compared to the untreated (Panel B).
















Figure 3. Quantitative analysis of estrogen’s effect on chlamydia infectivity. McCoy
cell monolayers were treated with 17 |3-estradiol (10 '*M) 24 hours prior to chlamydia
infection (10^ IFU/ml) (£+ blue). Estrogen caused an increase in chlamydia infectivity
compared to the untreated infected cells {E-, red) (p< 0.01).
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A. Control B. Chlamydia only C. Chlamydia and Estrogen
Figure 4. Analysis of estrogen effects on chlamydia infectivity in McCoy cells.
Immunoflorescence studies show a increase number of inclusion bodies (yellow
fluorescence, arrow) were observed in the infected cells pretreated with estrogen (Panel
C), compared to the untreated cells (Panel B). Panel A represents cells that were non-
infected and without estrogen treatment (40 x magnification).
Estrogen causes modulation of chemokine mRNA expression in Chlamydia infected
epithelial cells. Chemokines are small molecular weight proteins that attract leukocytes
to the site of infection. This usually occurs during the innate immune response against
chlamydia infection. To determine the effects of estrogen on chemokine mRNA
expression of infected cells, quantitative and semi-quantitative PCR was performed.
Quantitative PCR results established the upregulation of chemokines MIP-la, MIP-ip
and IP-10 in chlamydia infected McCoy cells. Figure 5 represents an agarose gel of the
PCR amplified product. Lanes 1-3 represent the expression ofMIP-la (Lane 1), MIP-ip
(Lane 2) and IP-10 (Lane 3) in the uninfected cells. Lanes 4-6 represent the expression
ofMIP-la (lane 4), MIP-1 p (lane 5), and IP-10 (lane 6). There was a fold-enhancement
in the mRNA expression ofMIP-la (3.86) and IP-10 (5.12) (Figs. 6-7).
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Figure 5. PCR optimization ofMoPn infected McCoy cells. There was an induction of
expression ofMlP-la in MoPn treated cells compared to the uninfected. (Lanes 1, MoPn
infected; Lane 4 uninfected), also caused a upregulation of MIP-ip (Lane 2) compared to
the uninfected cells (Lane 5). IP-10 was also upregulated in the MoPn infected (Lane 6)




Figure 6. The effect of chlamydia infection on MIP-la expression. McCoy cells were
treated with estrogen (10 * M) prior to chlamydia infection (10^ IFU/ml). Total RNA
isolated from cells 32 hours post infection were analyzed by quantitative RT-PCR to
assess the expression of level of MIP-1 a. PCR results indicated that there was a 3.86





Figure 7. The effect of chlamydia infection on IP-10 expression. McCoy cells were
treated with estrogen (10 * M) prior to chlamydia infection (10^ IFU/ml). Total RNAs
isolated from cells 32 hours post infection were analyzed by quantitative RT-PCR to
assess the expression of level of IP-10. PCR results indicated that there was a 5.12 fold
increase in the infected cells (red) compared to the non-infected cells (blue).
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Semi-quantitative results indicated that treatment ofMcCoy cells with estrogen followed
by chlamydia infection caused a decrease in the expression of chemokines. MIP-la
expression was down-regulated in the estrogen treated, infected cells (lane 1) compared
to the non-treated cells (lane 3) (Fig. 8A). The plots of the densitometric scans of the
data shown in Fig. 8B, was normalized to P-actin expression and analyzed
simultaneously at each point. Interestingly, estrogen pretreatment did not cause a
significant change (p > 0.02) in the expression ofMIP-lp in McCoy infected cells treated
with estrogen ( Fig. 9A; Lane 1) compared to the non-treated cells (Fig. 9A; Lane 3).
Results in Fig. 10 shows RANTES expression in the chlamydia non-treated McCoy cells
(Lane 2). There was a down-regulation of mRNA expression as shown in Lane 3.
Overall, estrogen caused a decrease in mRNA expression of RANTES, MIP-la and IP-




Figure 8. The effect of estrogen on mRNA expression of MIP-la in McCoy cells.
McCoy cells were pretreated with 17-P estradiol (10'* M) 24 hours prior to MoPn (10^
IFU/ml). Total RNAs isolated from cells 32 hours post infection were analyzed by semi-
quantitative RT-PCR to assess the level of expression of MlP-1 a. Estrogen caused a
decrease in MlP-la expression (Lane 1) compared to the non-treated infected cells (Lane
3). Lane 2 represents cells that were treated with estrogen only, there was a detectable
expression. Panel B represents the plot of the densitometric scans of the data shown in
panel A normalized to p-actin. E-, non-estrogen treated, chlamydia infected (blue); E+
estrogen treated, chlamydia infected (red).
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Figure 9. The effect estrogen on mRNA expression of MIP-ip in McCoy cells. McCoy
cells were pretreated with 17-P estradiol (10'* M) 24 hours prior to MoPn (10^ IFU/ml).
Total RNAs isolated from cells 32 hours post infection were analyzed by semi-
quantitative RT-PCR to assess the expression of level of MlP-ip. Estrogen did not
cause a change in MIP-ip expression {Lane 1) compared to the non-treated infected cells
{Lane 3). Panel B represents the plot of the densitometric scans of the data shown in
panel A normalized to p-actin. E-, non-estrogen treated, chlamydia infected (blue)', E+
estrogen treated, chlamydia infected (red).
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Treatment
Figure 10. The effect of estrogen on RANTES mRNA expression in MoPn infected
McCoy cells. McCoy cells were pretreated with 17-p estradiol (10'* M) 24 hours prior to
MoPn (10^ IFU/ml). Total RNAs isolated from cells 32 hours post infection were
analyzed by semi-quantitative RT-PCR to assess the expression of level of MlP-1 a.
Estrogen caused a decrease in RANTES expression (Lane 2) compared to the non-
treated infected cells (Lane 3). Panel B represents the plot of the densitometric scans of
the data shown in panel A normalized to P-actin. E-, non-estrogen treated, chlamydia
infected (blue); E+ estrogen treated, chlamydia infected (red).
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Estrogen causes modulation of chemokine production in Chlamydia infected epithelial
cells. In vitro studies indicated that estrogen increased chlamydia infectivity in epithelial
cells and caused a decrease in chemokines MIP-la, RANTES and IP-10 mRNA
expression. The purpose of these studies was to use ELISA to determine the effects of
estrogen on chemokine secretion in chlamydia infected epithelial cells. Cells were
treated with estrogen (10' M) for 24 hrs prior to chlamydia infection (10 IFU/ml).
Supernatant was collected 32 hours post infection and used for ELISA. Estrogen caused
a significant (p < 0.01) decrease in the production of MIP-la and a similar trend was
observed in RANTES and MCP-1 production (Figs. 11-13). Estrogen did not cause a
change in IP-10 production (Fig. 14). Overall, the greatest fold decrease was observed in




Figure 11. The effect of estrogen on MlP-la production during Chlamydia infection.
Cells pretreated with estrogen (10‘*M) 24 hours prior to MoPn infection resulted in lower
production ofMlP-la. ELISA was performed on the supernatant collected from cells 32
hours post infection. Estrogen caused a decrease in MIP-1 a production compared to the
non-treated. Standard deviation from 3 experiments. E-, no estrogen treatment,









Figure 12. Effects of estrogen on RANTES production during Chlamydia infection.
Cells pretreated with estrogen (10'* M) 24 hours prior to MoPn infection resulted in a
reduced secretion of RANTES. ELISA was performed on the supernatant collected from
cells 32 hours post infection. Estrogen caused a decrease in RANTES production
compared to the non-treated. Standard deviation from 3 experiments. E-, no estrogen
treatment, chlamydia infected (Red); E+, estrogen treated, chlamydia infected (blue).
**p<0.01
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Figure 13. The effeet of estrogen on MCP-1 production during Chlamydia infection.
Cells pretreated with estrogen (10'* M) 24 hours prior to MoPn infection resulted in
secretion of MCP-1. ELISA was performed on the supernatant collected from cells 32
hours post infection. Estrogen caused a decrease in MCP-1 production compared to the
non-treated. Standard deviation from 3 experiments. E-, no estrogen treatment,














Figure 14. The effect of estrogen on IP-10 production during Chlamydia infection.
Cells pretreated with estrogen (10'* M) 24 hours prior to MoPn infection did not produce
significant amount of IP-10. ELISA was performed on the supernatant collected from
cells 32 hours post infection. Estrogen caused a decrease in IP-10 production compared
to the non-treated. E-, no estrogen treatment, chlamydia infected (Red); E+, estrogen
treated, chlamydia infected (blue). Standard deviation from 3 experiments.
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Figure 15. Effect The effect of estrogen on chemokine production during Chlamydia
infection. MlP-la and RANTES showed a greater fold decrease in the presence of
estrogen.
Evaluation of the Effect of Estrogen on Course of infection and the Induction of
Protective Immunity in a Murine Model
Estrogen increases cervicovaginal shedding of C. trachomatis infected mice. Estrogen is
a sex hormone that has an effect on various immune effectors during chlamydia infection.
The effect of estrogen on the ability of mice to control and clear genital chlamydial
infection was investigated. Mice were treated with estrogen for 7 days prior to MoPn
infection. To follow the course of infection, mice were vaginally swabbed every three
days up to 30 days post infection. Chlamydia was isolated from the swabs and infectious
inclusion bodies were observed and enumerated using flourescence microscopy. Results
indicated that by day 12, there was a higher level of infection (logio 2.5 IFU/ml versus
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logiol.5 IFU/ml) in the estrogen treated animals compared to the non-treated animals
(Fig. 16). A similar trend of infection was observed at 15, 21 and 30 days post infection.
At 30 days, untreated animals resolved their infection; however there was sustained
infection in the estrogen treated mice (0.0 versus logic 1.0 IFU/ml, respectively).
Time (Days post-infection)
Figure 16. Effect of estrogen on Chlamydia infection in mouse model. Mice were
pretreated with 17P-estradiol (10’* M) prior to Chlamydia infection (10^ IFU) (E-, blue).
The course of infection was followed by performing vaginal swabs. Longer duration of
Chlamydia infection was observed in the estrogen treated mice compared to the
untreated. (E-, non-estrogen treated, chlamydia infected (red), E+, estrogen treated,
chlamydia infected (blue). Experiments were repeated 2 times to give 10-12 mice per
group.
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Estrogen Causes a Decrease in Chemokine Secretion during Chlamydia Infection in a
Mouse Model. The direct immunobiologic impact of estrogen may include the limitation
ofT cell activation and reduction or elimination of recruitment of leukocytes to the site of
infection. Since these processes are mediated by chemokines and cytokines, their
production in estrogen treated mice that were exposed to chlamydia was evaluated. Mice
were pretreated with estrogen for 7 consecutive days prior to chlamydia infection. At
various times post infection (7, 14, 21, and 38 days), the spleen was harvested. When
splenic cells containing T cells and other leukocytes were exposed to chlamydia, the
antigen-specific chemokine/cytokine response was decreased in the estrogen treated mice
compared to the wild-type mice. MIP-la production was significantly (p < 0.01)
decreased after estrogen treatment at 7-38 days post infection (Fig. 16). Figure 18
indicates that estrogen caused a decrease in MIP-ip production at 7,21 and 38 days post¬
infection. At 14 days, there was not a significant difference (p > 0.02) in MIP-ip
production in the estrogen treated and non treated mice. Moreover, RANTES production
was significantly lower (p < 0.01) in the estrogen treated mice compared to the non-
treated at 7, 14 and 21 days post infection (Fig. 18). No significant difference was
observed between the experimental groups at day 38. Intercellular adhesion molecule
type 1 (ICAM-1) production was affected by estrogen production as showing a decrease
at 7-38 days post infection (Fig. 20). Granulocyte macrophage-colony stimulating factor
(GM-CSF) is responsible for the maturation of dendritic cells. Estrogen treatment caused
a decrease in GM-CSF at 7, 14, 21, and 38 days post infection (Fig. 21). Collectively,
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estrogen had an overall significant effect on the production of these chemokines, some of













Figure 17. The effect of estrogen on MIP-la production during genital Chlamydia
infection in a mouse model. Estrogen treated(10'* M; E+, blue) and non treated red)
mice were infected with Chlamydia muridarum (the C. trachomatis agent of mouse
pneumonitis) and at various times post-infection (7, 14, 21 and 38 days) splenic cells
were isolated from infected mice and 2 x 10^ cells were stimulated with 10 pg/ml of
chlamydial antigen for 120 h. The supernatants were assayed using ELISA for MIP-la.
Estrogen caused a decrease in MIP-la production at 7, 14, 21, and 38 days post infection.
Data are mean ± standard deviation of triplicate cultures for each experiment; the results













Figure 18. The effect of estrogen on MIP-ip production during genital Chlamydia
infection in a mouse model. Estrogen treated (lO'^M; E+, blue) and non treated (E-, red)
mice were infected with Chlamydia muridarum (the C. trachomatis agent of mouse
pneumonitis). At various times post-infection (7, 14, 21 and 38 days) splenic cells were
isolated from infected mice and 2 x 10^ cells were stimulated with 10 pg/ml of
chlamydial antigen for 120 h. The supernatants were assayed using ELISA for MIP-ip.
Estrogen caused a decrease in MIP-1 p production at each time point post-infection during
Chlamydia infection in-vivo. Data are mean ± standard deviation of triplicate cultures for
each experiment; the results are derived from at least 3 independent experiments.
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Figure 19. Effects of estrogen on RANTES production during genital Chlamydia
infection. Estrogen treated (lO'^M; E+, blue) and non treated (E-, red) mice were
infected with Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis).
At various times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from
infected mice and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for
120 h. The supernatants were assayed using ELISA for RANTES. Estrogen caused a
decrease in RANTES production 7, 14, and 21 days post infection during Chlamydia
infection in-vivo. Data are mean ± standard deviation of triplicate cultures for each
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Figure 20. Effects of estrogen on ICAM-1 production during genital Chlamydia
infection. Estrogen treated (10'* M; E+, blue) and non treated (E-, red) mice were
infected with Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis).
At various times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from
infected mice and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for
120 h. The supernatants were assayed using ELISA for ICAM-1. Estrogen caused a
decrease in ICAM-1 production 7, 14, 21, and 38 days post infection during Chlamydia
infection in-vivo. Data are mean ± standard deviation of triplicate cultures for each




Figure 21. Effects of estrogen on GM-CSF production during Genital Chlamydia
infection in a mouse model. Estrogen treated (10'*M; E+, blue) and non treated (E-, red)
mice were infected with Chlamydia muridarum (the C. trachomatis agent of mouse
pneumonitis). At various times post-infection (7, 14, 21 and 38 days) splenic cells were
isolated from infected mice and 2 x 10^ cells were stimulated with 10 pg/ml of
chlamydial antigen for 120 h. The supernatants were assayed using ELISA for GM-CSF.
Estrogen caused a decrease in GM-CSF production 7,14, 21, and 38 days post-infection
during Chlamydia infection in-vivo. Data are mean ± standard deviation of triplicate
cultures for each experiment; the results are derived from at least 3 independent
experiments.
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Measurement of inflammatory cytokines secreted by T lymphocytes in estrogen treated
mice infected with genital chlamydia. Some cytokines induce the inflammatory processes
that have been associated with causing pelvic inflammatory disease, tubal scarring and
infertility during chlamydia infection. When splenic cells containing T cells and other
leukocytes from estrogen treated and non-treated mice were exposed to chlamydia, the
antigen specific interleukin-6 (IL-6), interleukin la (IL-la), tumor necrosis factor-alpha
(TNF-a) and IL-12 were measured in the supernatants using quantitative ELISA. Results
showed that the TNF-a level was low at 14 days post infection in the estrogen treated
compared to the non treated cells (Fig. 22). IL-6 levels were progressively lower in
estrogen treated animals 14, 21 and 38 days post-infection (Fig. 23). Observations
indicated that IL-la levels decreased at 7, 14, and 21 days post-infection in estrogen
treated mice (Fig. 24). There was no measurable IL-la production at 38 days post¬
infection. Moreover, decreased levels of IL-12 were observed in the estrogen treated
animals 14 and 21 days post-infection (Fig. 25). In summation, estrogen treatment
showed a trend in lowering the production of inflammatory cytokines. As mentioned
earlier, the inflammatory response has been correlated to the onset of pelvic
inflammatory disease and tubal factor infertility during repeated exposure to chlamydia.




Figure 22. The effects of estrogen on TNF-a production during genital Chlamydia
infection. Estrogen treated (lO'^M; E+, blue) and non treated {E-, red) mice were
infected with Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis).
At various times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from
infected mice and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for
120 h. The supernatants were assayed using ELISA for TNF-a. Estrogen caused a
decrease in TNF-a production 14 days post infection during Chlamydia infection in-vivo
(p 0.01). Data are mean ± standard deviation of triplicate cultures for each experiment;
the results are derived from at least 3 independent experiments.
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Figure 23. The effect of estrogen on IL-6 production during genital chlamydia infection.
Estrogen treated (10'*M; E+, blue) and non treated (E-, red) mice were infected with
Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis). At various
times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from infected mice
and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for 120 h. The
supernatants were assayed using ELISA for IL-6. Estrogen caused a decrease in IL-6
production (7, 14, 21 and 38 days postinfection) during Chlamydia infection in-vivo.
Data are mean ± standard deviation of triplicate cultures for each experiment; the results
are derived from at least 3 independent experiments.
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Figure 24. The effect of estrogen on IL-la production during genital chlamydia
infection. Estrogen treated (10'* M; E+, blue) and non treated (E-, red) mice were
infected with Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis).
At various times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from
infected mice and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for
120 h. The supernatants were assayed using ELISA for IL-la. Estrogen caused a
decrease in IL-la production (7, 14 and 21 days post-infection) during Chlamydia
infection in-vivo. Data are mean ± standard deviation of triplicate cultures for each
experiment; the results are derived from at least 3 independent experiments Estrogen





Figure 25. The effect of estrogen on IL-12 production during genital chlamydia
infection. Estrogen treated (10'* M; E-I-, blue) and non treated (E-, red) mice were
infected with Chlamydia murderer (the C. trachoma is agent of mouse pneumonitis). At
various times post-infection (7, 14, 21 and 38 days) splenic cells were isolated from
infected mice and 2x10^ cells were stimulated with 10 pg/ml of chlamydial antigen for
120 h. The supernatants were assayed using ELISA for IL-12. Estrogen caused a
decrease in IL-12 production (14 and 21 days pi) during Chlamydia infection in-vivo.
Data are mean ± standard deviation of triplicate cultures for each experiment; the results
are derived from at least 3 independent experiments. Estrogen caused a decrease in IL-12
production (14 and 21 days pi) during Chlamydia infection in-vivo.
Measurement of fertility in Estrogen treated mice during genital Chlamydia
Infection. The effect of estrogen on fertility in chlamydia infected mice was measured
approximately 19 days post mating. Mice were mated early (2 weeks) and late (5 weeks)
post-infection. There was no significant difference (p > 0.02) in the percentage of
pregnancy between the estrogen treated and the non-treated (67% E- vs. 60% E+) animals
%pregnant
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(Fig. 26A). A similar trend was observed in estrogen treated females that were mated
















Figure 26. The effect of estrogen on fertility during genital Chlamydia infection. Female
mice were treated with estrogen for 7 days prior to intravaginal infection with MoPn.
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Two weeks (panel A) and five weeks (panel B) post-infection females mated with males.
Nineteen days post mating females were sacrificed and evaluated for pregnancy.
Estrogen did not have a significant effect on the ability of infected animals to get
pregnant
Evaluation of the role of CCR5 in the immune response and pathogenesis during
Chlamydia infection
High intensity of infection and delayed clearance of genital chlamydial infection in
CCR5 deficient mice. CCR5 is a crucial chemokine receptor that supports the activation
and induction of specific T cells during infection and non-infection inflammatory
processes. We investigated the effect ofCCR5 deficiency on the ability ofmice to control
and clear genital Chlamydial infection. Figure 27 shows results from studies that
compared the course of genital chlamydial infection in the knockout (CCR5’^') and
control (wild type, WT) mice. The data revealed that within the first week of infection,
there was no difference in the ability of CCR5KO and WT mice to clear the infection.
However, by the second and fourth weeks, the ability of CCR5 mice to control the
infection was compromised, with a higher intensity of infection revealed by the isolation
of higher chlamydiae from the mice. By the fifth week, all WT mice had cleared the
infection but the CCR5KO mice remained infected (0.0 versus Logic 3.0 IFU/ml,
respectively). The results suggested that the deficiency of CCR5 could have adversely




Figure 27. Isolation of Chlamydia from CCR5 KO and wild type mice. Female
chemokine receptor CCR5 knockout (red) (CCR5KO or CCR5'‘^') and control CCR5
(blue) mice were intravaginally infected with 10^ IFU of MoPn. The status of the
infection was monitored by periodic cervico-vaginal swabbing of individual animals and
isolation of chlamydiae in tissue culture. Experiments were repeated 2 times to give 10-
12 mice per group.
Protection ofCCR5 deficient mice from certain complications of chlamydial infection
Repeated exposure to C. trachomatis has been known to cause ectopic pregnancy and
fallopian tube scarring leading to infertility in women. The absence of CCR5 will delay
the Th 1 response responsible for the clearance of chlamydia which may result in
ascending infection, thereby causing the previously mentioned symptoms. The effect of
the diminished capacity of CCRKO mice to clear genital chlamydial infection on the
infertility that is commonly associated with a genital infection was studied. Infected mice
were mated at two and five weeks after the initial infection, and the fertility was assessed
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by the number of pregnancies recorded. The mating at different time periods was targeted
at evaluating the short- and long-term effect of the infection on fertility, since the WT
mice cleared their infection at this latter time. Interesting, at 2 weeks post genital
infection, WT mice exhibited a significantly lower fertility (with < 40% pregnancy rate)
than CCR5KO mice (> 70%; p > 0.021) (Figure 22, panel A). Furthermore, at 5 weeks
post genital infection, all the CCR5KO mice exhibited 100% fertility whereas the control
mice scored approximately 50% (Figure 22, panel B). In addition, CCR5KO had a higher
number of pups in utero compared to the v^dld-type (Table 1). These results suggested
that the immunocompetence of the host is possibly a relevant factor in the development
of the long-term complication of chlamydial infection such as infertility. So we evaluated
the likely immune correlates of this inverse relationship between the ability to clear
chlamydial infection and the development ofcomplications.
A.
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wild type vs CCR5 KO
B.
Fertility in Wild type and CCR5 KO Mice mated 5 weeks post
infection
Figure 28. Fertility in CCR5 KO and wild type mice during genital Chlamydia infection.
Animals were infected with 10^ IFU of the MoPn. Two (A) and Five (B) weeks post
infection, groups of animals were mated with males, and subsequently observed for 19
days to determine pregnancy. The numbers of pregnant mice in the different groups were
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enumerated after 19 days in each case. Experiments were repeated 3 times with 6 mice
per experiment. W/T= wild-type control mice. CCR5KO=CCR5 knockout. Wild-type
(purple). Wild-type non-infected (blue), CCR5KO (Aqua), CCR5KO non-infected
(yellow)
Table 1. Average Number ofPups in CCR5 KO vs. Wildype during Genital Chlamydia
Infection
Animal Groups 2 wks post-infection 5 wks post-infection
CCR5 KO 8 ±2.1 6± 1.4
Wildtype 3± 1.9 2 ±3.3
Non-infected 7± 4.2 10 ±0.9
±S.D
Immunological correlates of clearance of infection and protection fi~om disease. The
direct immunobiologic impact of CCR5 deficiency includes the limitation of T cell
activation and recruitment of leukocytes to inflammatory sites of infection (Monno et al.
2001; Rockey et al. 2000). Since these processes are mediated by chemokines and
cytokines, their production by WT and CCR5KO leukocytes that are exposed to
chlamydiae, was evaluated. When splenic cells containing T cells and other leukocytes
were exposed to chlamydiae, the antigen-specific TNF-a response was expectedly
elevated in the cells from the WT mice (Fig. 29). The results presented in Figure 30 also
revealed that the level of antigen-specific IFN-y secreted by leukocytes from CCR5KO
mice was not statistically different from the levels secreted by leukocytes from non-
infected mice, indicating that that CCR5 is required for adequate activation of Thl
response against chlamydia. When the levels of the inflammatory chemokines RANTES
82
and IP-10 secreted by chlamydial exposed leukocytes from infected CCR5KO and WT
mice were compared, it was also found that the knockout mice exhibited a diminished
capacity (Figures 31 and 32), suggesting the deficiency of CCR5 results in a
compromised Thl response.
1200
CCR5KO infected Wildtype infected CCR5KO noninfected
Figure 29. Measurement of TNF-a production in CCR5 KO mice during genital
Chlamydia infection. Chemokine receptor knockout and control mice were genitally
infected with MoPn. At 2 weeks post infection splenic cells were isolated from infection
mice and 2 x 10^ cells were stimulated with 10 ug/ml of chlamydial antigen for 120 h.
The supernatants were collected and assayed for TNF-a. The absence of CCR5
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Figure 30. Measurement of IFN-y production in CCR5 KO mice during genital
Chlamydia infection. Chemokine receptor knockout and control mice were genitally
infected with MoPn. At 2 weeks post infection splenic cells were isolated from infection
mice and 2x10^ cells were stimulated with lOug/ml of chlamydial antigen for 120 h.
The supernatants were collected and assayed for IFN-y. The absence of CCR5 decreased
the amount of IFN-y produced.
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Figure 31. The production of RANTES in CCR5 KO mice during genital chlamydia
infection. Chemokine receptor knockout (CCR5KO) {blue) and control mice (purple)
were infected with Chlamydia muridarum (the C. trachomatis agent of mouse
pneumonitis). At various times post-infection (7, 14, 21 and 28 days) splenic cells were
isolated from infected mice and 2 x 10^ cells were stimulated with 10 pg/ml of
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Figure 32. The production of IP-10 in CCR5 KO mice during genital chlamydia
infection. Chemokine receptor knockout (CCR5KO) and control mice were infected with
Chlamydia muridarum (the C. trachomatis agent of mouse pneumonitis). At various
times post-infection (7, 14, 21 and 28 days) splenic cells were isolated from infected mice
and 2 X 10^ cells were stimulated with 10 pg/ml of chlamydial antigen for 120 h. The
supernatants were assayed using ELISA for IP-10.
CHAPTER 5
DISCUSSION
The pathological consequences of genital infection by Chlamydia trachomatis
include major sequelae, such as pelvic inflammatory disease and infertility. The urgent
need to develop an efficacious vaccine poses a major clinical and basic research
challenge of defining the requirements for inducing and maintaining protective genital
mucosal immunity. Recent studies of animal models indicated that rapid and early
elicitation and recruitment of certain immune effectors (specifically dendritic and Thl
cells) into local genital mucosae are crucial for antichlamydial immunity (Khamesipour
et al. 1994; Su et al. 1995; Igietseme 2003). Thus, strategies for the definition of novel
approaches to optimize the induction, recruitment, and retention of chlamydia-specific
Thl cells in genital mucosae are needed.
In general, the mucosal immime response to a vaccine is influenced by many
factors, such as the antigen, vector, adjuvant, route of delivery, and hormones associated
with the estrous cycle (for genital mucosal response) (Grayston 1962). It is conceivable
that these factors affect antigen uptake, mucosal immune induction and homing
recruitment, and retention of immune effectors in infected sites. Chemokines are
important mediators of leukocyte trafficking and of the controlled recruitment of specific
lymphocyte clonotypes during immune induction and inflammation. Epithelial cells and
certain other cell types comprising the innate immune effectors elaborate a
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number of cytokine and chemokines upon encountering mucosally routed antigens
(Amigorena et al. 1999; Guyre et al. 1997). Presently unknown, various factors may
regulate the expression and functions of certain chemokines, chemokine receptors, and
adhesion molecules. Sex hormones have been shoAvn to regulate the immune responses in
the female reproductive tract (McMurray 2001). The estrous cycle and treatment with
sex hormones such as estradiol and progesterone, have been demonstrated to influence
mucosal immune elicitation and flmction in the genital mucosal surface, cytokine
expression and recruitment or trafficking of leukocytes into the reproductive tract
(McMurry 2001). Moreover, epidemiologic and biologic evidence suggests that infection
with C. trachomatis, the leading cause of nongonococcal PID, is enhanced by oral
contraceptives (Washington 1985). The hypothesis investigated in the present study was
that estrogen alters the expression of immunoregulatory factors such as chemokines,
thereby affecting their roles in the induction and recruitment of leukocytes during
Chlamydia infection. The results revealed that estrogen suppressed the expression of
certain chemokines responsible for recruiting the relevant Thl and dendritic cells into
genital mucosae.
Studies in the mouse as well as other animal models have shown that hormones
play an important role in controlling immune responses to chlamydial infection and in
determining the outcome of infection (Palsey 1985; Rank 1987). In general, mouse
models require pretreatment with progesterone prior to exposure, to enhance infections,
especially with human serovars (Kaushic 2000). Others have shown that in the absence
of progesterone pretreatment, establishment of infection is dependent on stage of the
estrous cycle or requires high infectious doses (Bose and Goswami 1986). Guinea pigs
88
do not require progesterone and are easily infected with C. psitacci, but develop heavier
infection following estradiol treatment (Rank 1987). A basic understanding of the
mechanism by which estradiol is increasing chlamydia infectivity is greatly needed.
In vitro studies indicated that the pretreatment of estrogen causes an increase in
inclusion development (Fig. 4). These results confirmed earlier results by others
indicating that pretreatment of estrogen causes an increase in attachment and inclusion
development in HeLa cells and McCoy cells (Bose and Goswami 1986). Furthermore,
Wyrick and colleagues (2000) studies revealed that attachment of C. trachomatis is
approximately 50% in human endometrial gland epithelial cells. Addition of estrogen
(10‘*® M) to the culture medium enhanced chlamydial attachment to human endometrial
gland epithelial cells to approximately 80%. Understanding this increase in chlamydia
infectivity in cultured cells is of great interest. Recent studies have shown that protein
disulfide isomerase, a component of the estrogen receptor complex is associated with C.
trachomatis serovar E attachment to human endometrial epithelial cells (Wyrick 2000).
Localization studies performed by Sugarman (1986), suggested that the effect of estrogen
on the infectivity of C. trachomatis is dependent upon initial interactions of estrogens
with McCoy cells. In the same study, light and electron microscopy of the McCoy cells
showed no morphological changes after exposure to estrogen imder the incubation
conditions. Estrogen may modify host susceptibility to chlamydia infection in a marmer
independent of morphological changes in mammalian cells. These findings are of
importance because in an in vivo model, infection of epithelial cells causes initial action
of the innate immune response by the secretion of chemokines. Expression of
chemokines within tissues regulates the recruitment of specific subsets of lymphocytes to
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distinct tissue sites. Chemokines are therefore responsible, in part, for directing the
immune response that ensues following bacterial invasion. Epithelial cells play a central
role in directing the immune response, since they host Chlamydia and secrete cytokines,
such as IL-8, early after infection. The importance of the role these cells play in the
secretion of chemokines, led to our interest that estrogen may affect the production of
chemokines following Chlamydia infection. These data showed that pretreatment of
estrogen significantly decreased the production of MIP-la, RANTES and MCP-1 in
McCoy cells (Figs. 5-15). Interestingly, these are the first reported findings that indicate
estrogen’s effect on the expression of these chemokines in chlamydia infected cells.
These studies support other findings that determined the regulatory roles of sex hormones
in cutaneous biology and immunology in the skin. Studies indicated that estrogen in vitro
down-regulates the production of the neutrophil type 1 T cells and macrophage-attracting
chemokines, CXCL8, CXCLIO, CCL5, and RANTES by keratinocytes (Kanda 2003).
Findings of this investigation, led to the hypothesis that if estrogen causes a
decrease in the secretion of some of these chemokines in vitro then there would be a
similar trend in an animal model. This decrease could possibly have an effect on the
activation and recruitment of T lymphocytes to the site of infection, thereby affecting the
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induction of protective immunity. Wild-type mice were treated for seven days with 10'
M (10-fold higher than the physiological concentration) in mice followed by chlamydia
infection. Estrogen delayed the clearance of chlamydia compared to the wild-type (Fig.
16). These results are in accord with Rank and colleagues (1985) who suggested that
estradiol treatment increased the apparent number of infected cells in the cervix and
vagina. The chemokine profile data collected during this in vivo study supported the in
90
vitro findings, indicating that estrogen caused a decrease in MIP-la at 7, 14, 21, and 38
days (Fig. 17). The most obvious difference was observed at 21 days post-infection
which proves to be significant. According to some previous studies, approximately 14 to
21 days post-infection, there is a high expression of the CCR5 receptor in the T cells of
the genital tract of chlamydia infected mice. Similar findings were observed in the MIP-
ip and RANTES (Figs. 18 & 19). The production of RANTES was more significant at
21 days post-infection. The obvious increase in production of these chemokines at 21
days post-infection have also been observed in other studies performed in the lab by
Belay et. al (2002). These studies indicated the expression ofRANTES, MCP-1, MIP-la,
IP-10 early in infection. Interestingly, there was a robust production of RANTES in the
estrogen treated animals around 7 days post-infection. The explanation for this response
is unknown. It could possibly be attributed to a high nonspecific response or could be
due to factors that are to be determined in future studies.
The role of estrogen in the regulation of the inflammatory response is not well
defined as it relates to chlamydia infection. It was observed that estrogen decreased the
production of inflammatory cytokines IL-6, IL-la, and TNF-a (Figs. 22-24). These
results could be significant because of the correlation between chlamydia infection and
PID which results from inflammatory response (Barr et al. 2005). The immune response
to genital chlamydial infection is very complex: it clears infection and confers short term
protection but at the same time sensitizes the host for development of
immunopathological changes (Kaushic et. al 2005). Williams and colleagues (1998)
showed that IL-6 KO mice had significantly increased C trachomatis levels in lung
tissue and increased mortality compared to wildtype controls early after intranasal
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infection. Other studies have shown that IL-la and TNF-a which play indirect roles in
leukocyte recruitment by upregulating ICAM-1, E-selectin and VCAM-1 on adjacent
endothelia (Lovdal et al. 2000). Moreover, TGF-a, TNF-a and large quantities of IL-la
and IL-6 have been associated with scarring and fibrosis in animal models and humans
(Lanzavecchia 1996; Lovdal et al. 2000). This information raises the possibility that
Chlamydia-infected epithelial cells directly contribute to scarring of the fallopian tubes.
(Johnson 2004)
In view of the fact that estrogen decreases the production of infiammatory
cytokines, there may be a positive effect on the immunopathology that is usually
associated with infertility. When this hypothesis was tested, surprisingly, estrogen did not
have an effect on the pregnancy rates during Chlamydia infection. These studies are
supported by other studies that showed oral contraceptives did not affect the duration of
shedding of organisms nor the histopathology of acute chlamydial infection of the
reproductive tract (Kaushic et al. 2000). The results suggest that although estrogen
decreases inflammatory responses, there is not a significant effect on the
immunopathology that is usually associated with the influx of inflammatory cells (Fig.
26). There may be other mechanisms by which infertility is occurring. Further studies
could possibly investigate the effect of pre-treatment and post-treatment of estrogen on
the effects of pregnancy. Ongoing experiments in the laboratory are studying the effects
of pregnancy on chlamydia infection. Others have evaluated the effect of C. trahomatis
on pregnancy which resulted in low birth weight births and/or stillbirths (Rastogi 2003),
Lawton et al. 2004).
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Similar studies have shown that estrogen treatment down-regulates TNF-a
produetion and reduees the severity of experimental autoimmune encephalomyelitis in
cytokine knockout mice (Ito et al. 2001). Studies have indicated that estrogen treatment
may possibly cause a shift to Th 2 production; however, that was not the case in this
study.
In addition, estrogen had a significant effect on GM-CSF (granulocyte
macrophage colony stimulating factor) secretion which is responsible for the maturation
of dendritic cells which act as antigen presenting cells (Fig. 21). GM-CSF is produced by
T cells, B cells, macrophages, mast cells, endothelial cells, neutrophils, eosinophils, and
fibroblasts, when these cells are stimulated by certain cytokines or other factors during
inflammation. GM-CSF is a pleiotropic cytokine that promotes the proliferation,
maturation, and activation of different hematopoietic cells at various developmental
stages. This could prove to be significant because earlier studies have indicated that
estradiol regulates antigen presentation by vaginal cells and that vaginal cells, in turn,
influence antigen presentation, as well as B and T cell proliferation (Wira et al. 2000).
Estrogen decreased ICAM-1 production (Intercellular adhesion molecule type-1)
in the genital tract of chlamydia infected mice (Fig. 20). These findings are significant
because earlier studies in the laboratory of Joseph Igietseme revealed that ICAM-1
showed a pattern of expression in the genital tract of noninfected control mice and
chlamydia infected mice (Belay et al. 2002). The expression followed the expression
patterns of Thl-related chemokines, peaking by day 21 and appearing to be reduced by
day 42 (Belay et al. 2002). Adhesion molecules enhance adherence of the T cell to the
APC/target cell transmembrane proteins or glycoproteins. Adhesion molecules on one
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cell interact with complementary adhesion molecules on the other cell. T cell activation
is imperative in the clearance of chlamydia. These results might suggest that estrogen
may act as an immunosuppressor by decreasing the production of ICAM-1 which would
in turn interfere with antigen presentation and or T cell activation. Further studies are
needed in order to determine the mechanism by which estrogen may be effecting the
expression of this molecule. Earlier findings have suggested that one of the mechanisms
by which estrogen decreases parthogenesis is by the suppression of vascular cellular
adhesion molecule-1 (VCAM-1) expression, which leads to decreased macrophage
recruitment to the arterial wall early in the process. (Seli et al. 2002).
The effects of estrogen on infectivity or immune response toward foreign agents
is not unambiguous for chlamydia, but other bacteria causing diseases such ais gonorrhea
have been of great concern for those who are on oral contraceptives. In mice treated with
estradiol, bacteremia progressively developed within 12h post inoculation and mice died
within the next 6 h. The administration of estradiol affected by the function of
polymorphonuclear leukocytes (PMN) responsible for eliminating gonococci, but the
progesterone did not (Kita et al. 1981).
As mentioned earlier, estrogen had a significant effect on the production of
RANTES, MIP-la and MIP-ip. These chemokines are ligands with high affinity for
CCR5. Interestingly, recent findings indicate that chemokine receptors such as CCR5 act
as CO receptors (with the CD4 molecule) for entry of the human immunodeficiency virus
(HIV). In other similar studies, estrogen treatment significantly decreased expression of
proteins corresponding to the chemokine receptors CXCR3 and CCR5 on mammary
cells. Results suggested that exposure ofmammary tissue to estrogen may decrease the
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release of local chemokines from mammary cells; potentially increasing the risk of tumor
growth through decreased immune surveillance (Aronica et al. 2004).
For the aforementioned reasons, chemokine receptor-5 was of particular interest
in our study. We chose to determine its role in the induction of protective immunity
against chlamydia. Studies have shown that CCR5-deficient mice were significantly
more susceptible to infections with the parasites Listeria monocytogenes. Cryptococcus
neoformans, and Toxoplasma gondii. They also showed increased mortality to influenza
A virus infection (Mack et al. 2001). Belay et al. (2002) found that T cells expressed
CCR5 during genital chlamydia infection. This led to the hypothesis that CCR5 may
play a vital role in the induction of protective immimity. In this study, we have
experimentally demonstrated that the CCR5-related inflammatory response is crucial for
the development of tubal factor infertility (TFI) following genital chlamydial infection.
In translational immunogenetic and pathobiologic clinical studies in humans, functional
defect in CCR5 also appears to moderate the development of tubal pathogenesis
associated with genital chlamydial infection in women. These data are corroborated by
previous propositions that certain host factors are relevant for the development of the
complications of chlamydial infection. Specifically, the 32 bp deletion in the CCR5
gene, which results in a truncated protein with impaired signal-transduction capacity, was
associated with resistance to human immunodeficiency virus type 1 (HIV-1) infection
(Kinnunen et al. 2003; Dean et al. 1996). Recently, it has been suggested that
heterozygosity for CCR5delta32 was also associated with spontaneous hepatitis C viral
clearance and with significantly lower hepatic inflammatory scores (Goulding et al.
2005). These experimental studies indicated that a deficiency of specific antichlamydial
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Thl response led to a suppression of Thl response and delayed clearance of genital
chlamydial infection. However, CCR5KO mice were protected from the complications
of the genital infection relating to infertility (Fig. 28). In addition, C. trachomatis-
exposed women with CCR5delta32 deletions appear to be protected from tubal pathology
as well, suggesting a crucial role for CCR5-related specific Thl and inflammatory
responses in the pathogenesis of infectious tubal pathologies. Similar findings have
shown that the lack of CCR5 reduced the number of ulcerations in dextran-sulfate-
mediated colitis and increased the tolerance to LPS (Mack et al. 2001).
Perhaps this study represents the first concurrent demonstration of a strong causal
relationship between CCR5-related specific Thl and inflammatory response and
development of complications of genital chlamydial infection in both animal models and
humans. The implications include the fact that although Thl response is crucial for
chlamydial control, there are host conditions that could skew the response toward
pathology. Such conditions may include the involvement of immunopathogenic
chlamydial antigens (LaVerda et al. 1997) and vaccine design effort may focus on
defining the existence of clonotypic T cells that recognize such antigens or develop
additional strategies to eliminate them from promising vaccine candidates. T eell clones
reactive against specific chlamydial antigens have been isolated from the synovial fluids
of patients suffering from chlamydia-indueed reactive arthritis (Hassel et al. 1993). In
addition, since an early and relatively robust T cell response is protective against
subsequent development of complications of chlamydial infection (Igietseme 2003), these
results from the CCR5KO system may suggest that the lack of an early T cell activation
caused the delay in resolution of the infection; however, the persisting suppression of T
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cell activation prevented the chronic host inflammatory response that induces
pathologies. Therefore, an early treatment of chlamydial infection with antimicrobials
followed by specifically targeted anti-inflammatory agents may hold promise as a
strategy for preventing the complications of chlamydial infection. Finally, it is pertinent
to mention that although previous studies along this proposition yielded conflicting
results, the selective use of specifically targeted anti-inflammatory agents in combination
with antibiotics could prove useful in the management of chlamydial infections to avert
pathology. In fact, inflammatory processes induced by several species of Chlamydia
could be suppressed by certain non-steroidal anti-inflammatory drugs, including aspirin
and indomethacin.
In summation, this study has revealed novel results indicating the influence of
estrogen and CCR5 on the immune response against chlamydia. This is the first study
to show the effect of estrogen on inflammatory cytokine production during genital
chlamydia infection. These findings may be helpful in developing therapeutic treatments
protecting infected women from the development of inflammation that is associated with
PID. In addition, the role of Thl chemokines/chemokine receptor-5 proved to be vital in
their ability to activate and recruit T lymphocytes to the site of infection. These data
could be useful in the designing and development of a vaccine. Modulation of specific
chemokines and their specific receptors (i.e. CCR5 and CXCR3 for Thl and CCR3 for
Th2) can therefore be useful in promoting the induction and recruitment of Thl cells into
the genital mucosa to ensure protective immunity against Chlamydia (D’Ambrosio et al.
2000). Although promising, the impact of conditionally expressed chemokines as an
adjuvant system in a vaccine construct to modulate mucosal immune response against
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Chlamydia has yet to be determined. However, despite the presence of chemokines and
CD4*^ Thl cells in the upper genital tract, infected mice still suffer ascending infection,
suggesting that the immune response elicited in the upper genital tract remains
insufficient to control the spread of chlamydiae from the lower to the upper genital tract
(Belay et al. 2002; Maxion and Kelly 2002).
To date, scientists have developed recombinant multi-subimit vaccines using
chlamydia antigens (OMPl and PORB) (Eko et al. 2002). Various adjuvant systems
have been used and presently in our laboratory we have been evaluating the use of
recombinant technology to engineer Lactobacillus as a potential delivery vehicle for
chlamydia antigen(s) and adjuvant system. By including gene sequences for chemokines
such as RANTES, MIP-la and IP-10 in a recombinant plasmid may prove useful in the
induction, recruitment, and retention of chlamydia-specific Thl cells in genital mucosae.
Further studies are needed to evaluate the immunogenicity and protective properties of
such a vaccine.
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